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ABSTRACT
The pentose phosphate pathway (PPP) is a fundamental component of cellular metabolism. The PPP is important to
maintain carbon homoeostasis, to provide precursors for nucleotide and amino acid biosynthesis, to provide reducing
molecules for anabolism, and to defeat oxidative stress. The PPP shares reactions with the Entner–Doudoroff pathway
and Calvin cycle and divides into an oxidative and non-oxidative branch. The oxidative branch is highly active in
most eukaryotes and converts glucose 6-phosphate into carbon dioxide, ribulose 5-phosphate and NADPH. The latter
function is critical to maintain redox balance under stress situations, when cells proliferate rapidly, in ageing, and for the
‘Warburg effect’ of cancer cells. The non-oxidative branch instead is virtually ubiquitous, and metabolizes the glycolytic
intermediates fructose 6-phosphate and glyceraldehyde 3-phosphate as well as sedoheptulose sugars, yielding ribose
5-phosphate for the synthesis of nucleic acids and sugar phosphate precursors for the synthesis of amino acids. Whereas
the oxidative PPP is considered unidirectional, the non-oxidative branch can supply glycolysis with intermediates
derived from ribose 5-phosphate and vice versa, depending on the biochemical demand. These functions require dynamic
regulation of the PPP pathway that is achieved through hierarchical interactions between transcriptome, proteome and
metabolome. Consequently, the biochemistry and regulation of this pathway, while still unresolved in many cases, are
archetypal for the dynamics of the metabolic network of the cell. In this comprehensive article we review seminal work
that led to the discovery and description of the pathway that date back now for 80 years, and address recent results
about genetic and metabolic mechanisms that regulate its activity. These biochemical principles are discussed in the
context of PPP deficiencies causing metabolic disease and the role of this pathway in biotechnology, bacterial and
parasite infections, neurons, stem cell potency and cancer metabolism.
* Address for correspondence (Tel: +44 1223 761346; E-mail: mr559@cam.ac.uk).
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
928 A. Stincone and others
Key words: pentose phosphate pathway, glycolysis, glucose 6-phosphate dehydrogenase, NADPH, metabolomics,
oxidative stress, cancer, stem cells, host–pathogen interactions, metabolic engineering, inherited metabolic disease,
parasitic protozoa, metabolism of infection.
CONTENTS
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 929
II. Biochemistry and evolutionary origin of the pentose phosphate pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 929
(1) The L-type PPP and alternative or extended reaction sequences of the PPP . . . . . . . . . . . . . . . . . . . . . . . . . . . 932
(2) The subcellular localization of the PPP and its enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 932
(3) Glucose 6-phosphate dehydrogenase (G6PDH) and the role of the oxidative PPP in NADPH synthesis 932
(a) Non-PPP sources of NADP(H) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 933
(b) The synthesis of ribulose 5-phosphate in the non-oxidative PPP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 934
III. The glycolysis/PPP transition: metabolic and transcriptional mechanisms that change PPP flux upon
demand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 934
(1) Regulation of the PPP during the oxidative stress response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 935
(2) Transcriptional regulators of the PPP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 936
(3) Feedforward regulation of the metabolome to the transcriptome: PPP metabolites as regulators of the
stress response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 937
IV. Analytical methods for measurement of PPP intermediates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 937
(1) From historical techniques to LC-MS/MS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 937
(2) In vivo PPP measurements using NMR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 938
V. The PPP in biotechnology: metabolic engineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 938
VI. Inborn errors within PPP enzymes that lead to human metabolic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 939
(1) G6PDH deficiency, the most common human enzyme defect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 939
(2) RPI deficiency, the currently rarest human disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 939
(3) TAL deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 940
(4) GPI deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 941
(5) TPI deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 941
(6) Hexose 6-phosphate dehydrogenase (H6PDH) deficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 942
VII. Host–pathogen interactions: the role of the PPP in infectious disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 942
(1) The PPP as a target in parasitic protozoa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 942
(a) Kinetoplastids, the trypanothione pathway and the compartmentalization of the PPP in glycosomes 943
(b) Plasmodium spp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 943
(c) The alternative PPP of Entamoeba histolytica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 945
(2) The PPP in bacterial infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 945
(a) The PPP is required in the host response to fight microbial infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 945
(b) The PPP is a central pathway for bacterial infection and LPS biosynthesis . . . . . . . . . . . . . . . . . . . . . . . . 945
VIII. The role of the PPP in cell proliferation and stem cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 946
(1) The role of the PPP in deregulated cell proliferation and the pathogenesis of cancer: the Warburg effect 947
(2) Evidence for enhanced PPP activity in cancer cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 948
(3) Enzymatic switches enable metabolic adaptation of cancer cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 949
(4) Interaction of the PPP with oncogenic pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 949
(a) p53 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 949
(b) ATM kinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 950
(c) K-ras . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 950
(d ) HIF-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 950
(e) PI3K-Akt/mTORC1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 951
(f ) Alternative pathways of PPP activation in cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 952
(5) Conclusions about the role of the PPP in cancer metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 952
IX. The role of the PPP in brain energy metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 952
X. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 954
XI. Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 954
XII. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 954
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
The pentose phosphate pathway 929
I. INTRODUCTION
Next to glycolysis (Embden–Meyerhof–Parnas pathway)
and the tricarboxylic acid (Krebs) cycle, the pentose
phosphate pathway (PPP) was one of the first metabolic
pathways to be discovered. Work on the PPP was stimulated
by the famous Otto Warburg laboratory in Berlin-Dahlem.
In the 1930s Warburg demonstrated that the pyridine
nucleotide diphosphopyridine nucleotide DPN (now known
as NAD+) functions as an electron carrier (Warburg,
Christian & Griese, 1935; Warburg & Christian, 1936).
In addition, this work revealed the existence of a second
coenzyme, termed triphosphopyridine nucleotide TPN (now
widely known as NADP+), that is required for the oxidation
of glucose 6-phosphate to 6-phosphogluconate, by an
enzyme which was purified from yeast and erythrocytes and
named Zwischenferment [‘intermediate enzyme’ now glucose
6-phosphate dehydrogenase (G6PDH)] (Warburg et al.,
1935; Warburg & Christian, 1936; Dickens, 1938). The TPN
dependence of the Zwischenferment led to the speculation
that there might be a pathway parallel to glycolysis, involved
in the direct oxidation of glucose (reviewed by (Horecker,
2002)). Work in the subsequent three decades, driven
substantially by Bernard Horecker at Cornell University, but
with important contributions by other leading biochemists
including Arthur Kornberg, Terry Wood, Frank Dickens,
Fritz Lipmann, Severo Ochoa, Hans Klenow and others,
yielded a draft version of the pathway that was presented in
1955 (Gunsalus, Horecker & Wood, 1955). However, it took
further decades to complete the canonical pathway map as we
know it today, with some enzymes being added only recently
[i.e. sedoheptulokinase (SHPK) in humans (Wamelink et al.,
2008b) and sedoheptulose 1,7 bisphosphatase (SH17BPase)
in yeast (Clasquin et al., 2011)]. Meanwhile, the PPP has
gained recognition as being a central player in cellular
biosynthetic metabolism and in controlling and maintaining
the redox homeostasis of cells. As such, it has been implicated
in several human diseases including metabolic syndrome,
neurodegeneration (Alzheimer’s disease), cardiovascular
disease, parasite infections and cancer (Wood, 1985;
Zimmer, 1992; Zimmer, 2001; Schaaff-Gerstenschlager &
Zimmermann, 1993; Gupte, 2008; Mayr et al., 2008; Oresˇicˇ
et al., 2011; Vander Heiden et al., 2011; Riganti et al., 2012;
Wallace, 2012).
II. BIOCHEMISTRY AND EVOLUTIONARY
ORIGIN OF THE PENTOSE PHOSPHATE
PATHWAY
The biochemical reactions that constitute the PPP are,
evolutionarily speaking, very old, and seem to accompany life
since the earliest steps of evolution. Indeed, metal-catalysed
enzyme-free reactions analogous to the PPP are observed
in a reconstructed reaction milieu of the prebiotic
Archean ocean. This indicates that the basic structure
of the PPP is of pre-enzymatic origin and may descend
from chemically constraint pre-biotic metal-catalysed sugar
phosphate interconversions (Keller, Turchyn & Ralser,
2014). The modern cellular PPP however is catalysed by
sophisticated enzymes, except one step, the interconversion
of 6-phosphoglucono-δ-lactone to 6-phosphogluconate,
which is still considered at least partly spontaneous (Wood,
1985; Horecker, 2002). These enzymatic reactions subdivide
the PPP into two biochemical branches, known as the
oxidative and non-oxidative PPP (see Fig. 1 for an overview
of the pathway, and Table 1 for its enzymes).
Reactions of the non-oxidative PPP (with the overlapping
Calvin cycle and Entner–Doudoroff pathways), occur
virtually ubiquitously, and maintain a central metabolic
role in providing the RNA backbone precursors ribose
5-phosphate and erythrose 4-phosphate as precursors for
aromatic amino acids. By contrast, the oxidative branch of
the PPP is not universal and is absent in many aerobic and
thermophilic organisms (Grochowski, Xu & White, 2005;
Nunoura et al., 2011; Bra¨sen et al., 2014). While reactions of
the non-oxidative branch can also occur non-enzymatically,
reactions concerning the interconversion of glucose
6-phosphate to 6-phosphogluconate, defining the oxidative
PPP, were not observed in the Archean ocean simulations
(Keller et al., 2014). This observation might indicate that
the oxidative part of the PPP pathway is evolutionarily
newer than the non-oxidative branch. Nonetheless, in the
majority of eukaryotes the oxidative branch is highly active
and converts the glycolytic/gluconeogenetic metabolite
glucose 6-phosphate into ribulose 5-phosphate via the
consecutive reactions of G6PDH [in yeast still named Zwf1
(ZWischenFerment) in acknowledgement of Otto Warburg’s
original nomenclature], 6-phosphogluconolactonase (6PGL)
[catalysing a reaction which can also occur spontaneously
but the enzyme increases its specificity (Miclet et al., 2001)]
and 6-phosphogluconate dehydrogenase (6PGDH). This
metabolic sequence yields two NADPH per metabolized
glucose 6-phosphate. Next, the formed ribulose 5-phosphate
enters the non-oxidative branch and can be converted either
to ribose 5-phosphate by ribose 5-phosphate isomerase
(RPI) or to xylulose 5-phosphate by ribulose 5-phosphate
epimerase (RPE). While ribose 5-phosphate is required to
form the RNA and DNA backbone, erythrose 4-phosphate
is required as precursor for the biosynthesis of histidine,
for various aromatic metabolites in aromatic amino acid
prototrophic organisms and it plays a role in vitamin B6
metabolism (Zimmer, 1992; Wang, Xie & Schultz, 2006;
Cadie`re et al., 2011; Clasquin et al., 2011; Zhao et al., 1995).
The RPI and RPE reactions set the stage for completing
the pathway though conversion of ribose 5-phosphate and
xylulose 5-phosphate and the glycolytic/gluconeogenetic
intermediates glyceraldehyde 3-phosphate and fructose
6-phosphate via reshuffling of the monophosphate sugars.
These reactions are catalysed by the two enzymes
transketolase (TKL) and transaldolase (TAL), which
are responsible for relatively complex (multi-substrate)
interconversion reactions at the core of the non-oxidative
PPP (Fig. 1).
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Fig. 1. Schematic representation of the pentose phosphate pathway (PPP, left) and glycolysis (canonical topology of the
Embden-Meyerhof-Parnas pathway) (right). The enzymatic reactions constituting both pathways are represented by double or
single arrows, according to the reversibility of the reactions. The oxidative and non-oxidative branches of the PPP are highlighted
by background coloring. Sedoheptulose conversion enzymes found in *bacteria; **fungi (S. cerevisiae) and plants, ***mammals.
Abbreviations are defined in Table 1; FBA, fructose bisphosphate aldolase; HK, hexokinase; PFK, phosphofructokinase; PK,
pyruvate kinase; SH17BP, SH17BPase.
TKL uses a ketose donor (xylulose 5-phosphate) and
aldose acceptors (ribose 5-phosphate or erythrose 4-
phosphate) to form aldose and ketose products (glycer-
aldehyde 3-phosphate and sedoheptulose 7-phosphate or
fructose 6-phosphate, respectively), to catalyse the transfer
of two-carbon fragments (‘activated glycolaldehyde’) for
monosaccharide interconversion (Schenk, Duggleby &
Nixon, 1998). Hence, this enzyme is responsible for two dis-
tinct reactions within the non-oxidative PPP. TKL activity is
dependent on the cofactor thiamine diphosphate (Lindqvist
et al., 1992; Schenk et al., 1998; Kochetov & Sevostyanova,
2005). The cofactor is bound at the interface between the two
subunits of TKL a homodimer, with two identical catalytic
sites (Lindqvist et al., 1992; Kochetov & Sevostyanova, 2005).
TAL instead catalyses the transfer of the three-carbon
fragment dihydroxyacetone between sugar phosphates up
to eight carbons in length via the formation of a Schiff
base at a lysine residue in the active site (Miosga et al.,
1993; Banki & Perl, 1996; Samland & Sprenger, 2009). Its
donor substrates are ketose sugar phosphates which include
fructose 6-phosphate and sedoheptulose 7-phosphate and
its acceptor substrates are the aldose sugar phosphates
glyceraldehyde 3-phosphate and erythrose 4-phosphate
(Samland & Sprenger, 2009).
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By sharing these intermediate metabolites with glycolysis
(fructose 6-phosphate and glyceraldehyde 3-phosphate),
TAL and TKL act as a bridge between glycolysis and the
PPP. In addition, they connect to sedoheptulose 7-phosphate
which is synthesized also by other sources. These include
the recently described enzyme sedoheptulokinase [SHPK,
also known under the former systematic name carbohydrate
kinase-like (CARKL)] in mammals (Kardon et al., 2008;
Wamelink et al., 2008b). SHPK catalyses the phosphorylation
of sedoheptulose to sedoheptulose 7-phosphate though ATP
consumption in a biochemical reaction first described in
1955 (Ebata, Sato & Bak, 1955). Other novel enzymes that
metabolize sedoheptulose 7-phosphate are sedoheptulose
1,7-bisphosphatase (SH17BPase) in yeast (Clasquin et al.,
2011) and sedoheptulose 7-phosphate isomerase (SHI)
in bacteria (Kneidinger et al., 2001; Valvano, Messner &
Kosma, 2002; Taylor et al., 2008). Hence, sedoheptulose
7-phosphate represents a glycolysis-independent entry and
exit point into/from the non-oxidative PPP. The formation
of this metabolite connects the PPP with open chain and
polyol sugar metabolism and bacterial lipopolysaccharide
biosynthesis. These connections with both glycolysis, amino
acid biosynthesis and open-chain sugar metabolism place
the PPP central to the metabolic network. Moreover, its
flux and regulation not only depend on, but also influence
its neighbouring metabolic routes, which might explain in
part the extensive regulation of this biochemical route, as
detailed in later sections of this article.
Analysis in yeast and mammalian cells has shown that
with the exception of RPI, most of the PPP enzymes are not
essential for survival at the cellular level. At the organism
level in mammals, at least partial deficiencies of PPP enzymes
G6PDH, 6PGDH, TAL and RPI are viable as well, but lead
to severe genetic disease (see Section VI). However, no disease
phenotypes or deficiencies have been reported for the other
PPP enzymes; most likely their deficiency is embryonically
lethal to mammalian organisms, indicating that the PPP
as pathway is essential. Indeed, double gene deletions that
affect both the oxidative and the non-oxidative PPP are also
lethal down to the cellular level (Schaaff-Gerstenschlager
& Zimmermann, 1993; Juhnke et al., 1996; Kru¨ger et al.,
2011). The viability of the partial PPP deficiencies and
several null alleles therefore indicates that the oxidative and
non-oxidative branches of the PPP can work independently;
each of the two parts can compensate and provide sufficient
sugar phosphate precursors required for cellular survival.
(1) The L-type PPP and alternative or extended
reaction sequences of the PPP
The PPP might also exist in alternative reaction
sequences. Named the L-type PPP, a reaction sequence
was proposed in liver cells that involves flux over
alternative metabolites such as arabinose 5-phosphate and
glycero-ido-octulose phosphate (Williams et al., 1984). Also,
alternative seven-carbon phosphates and their diphosphates
have been associated with the PPP (Wood, 1985).
(Longenecker & Williams, 1980) suggested that up to 30%
of the PPP flux in hepatocytes could be attributable to
these alternative PPP forms. Nevertheless, there is only
limited confirmation of these PPP alternatives, indeed
biochemical evidence for them has been questioned
(Landau & Wood, 1983). Therefore, these alternatives are
not addressed in detail herein. The recent discovery of
the PPP enzymes SHPK and the SH17BPase however
indicates that the full biochemical spectra of the PPP
could exceed the core reactivity of the canonical pathway
(Fig. 1), and hence that additional discoveries might still be
made.
(2) The subcellular localization of the PPP and its
enzymes
In most organisms, including fungi and metazoa, the PPP
is localized in the cytosol, and contributes both to the
cytoplasmic metabolite as well as redox cofactor pool.
However, important exceptions do exist. The pathway is
split between the cytosol and other organelles such as the
plastid, peroxisomes or glycosomes in plants and parasitic
protozoa, respectively (Zimmer, 2001; Hannaert et al., 2003;
Kruger & von Schaewen, 2003). Part of the PPP might
occur in the endoplasmic reticulum (ER) too. Microsomes,
vesicles formed from the ER when cells are mechanically
homogenized, contain at least five PPP enzymes. These
include hexose 6-phosphate dehydrogenase (H6PDH), an
enzyme similar to G6PDH (Bublitz & Steavenson, 1988;
Nelson, Lehninger & Cox, 2008; Senesi et al., 2010) that
is required to provide NADPH to the luminal reductases
(Beutler & Morrison, 1967; Takahashi & Hori, 1978; Senesi
et al., 2010). H6PDH has a broader range of substrates
than G6PDH and it was described as being non-selective
regarding the nucleotide cofactor (NAD+ and NADP+).
The concentration of reduced NADP(H) in the endoplasmic
lumen suggested that under physiological conditions glucose
6-phosphate and NADP+ are preferred. Hence, while the
PPP is largely a cytosolic pathway, alternative organelle
localisations do exist and are of significant importance.
(3) Glucose 6-phosphate dehydrogenase (G6PDH)
and the role of the oxidative PPP in NADPH
synthesis
The most intensively studied enzyme of the PPP is G6PDH,
an NADP+-dependent oxidoreductase. This enzyme has
often been quoted as being rate limiting for the oxidative
branch of the PPP. Although the classic concept of ‘rate
limitation’ has its limitations (Kacser, 1995), the first
enzymatic step involving G6PDH is certainly of central
importance as the oxidative PPP is largely considered
unidirectional. Eukaryotic G6PDH was first discovered in
different strains of brewery yeast (Dickens, 1938), and to
date this model organism has served for dissecting most
of the functionality of the PPP. Budding yeast G6PDH is
encoded by a single gene YNL241C (Nogae & Johnston,
1990; Thomas, Cherest & Surdin-Kerjan, 1991). Deletion
of this gene retains viability, but zwf1 cells are unable to
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synthesize methionine. It is assumed that this methionine
auxotrophy is a consequence of the insufficient production
of NADPH to sustain methionine biosynthesis, and requires
yeast to assimilate ‘inorganic sulphur’ in order to form
‘organic sulphur’ (methionine or cysteine) to grow (Masselot
& De Robichon-Szulmajster, 1975; Nogae & Johnston, 1990;
Thomas et al., 1991). This notion of NADPH shortage in
zwf1 cells is supported by the observations that (i) when
supplying NADPH from a different source, i.e. through
alcohol dehydrogenase (Ald6), the methionine prototrophy
is restored (Grabowska & Chelstowska, 2003). Moreover
(ii), also yeast cells deleted for cytoplasmic superoxide
dismutase (SOD1) become methionine auxotrophs (Slekar,
Kosman & Culotta, 1996). These results indicate that
G6PDH, and the oxidative PPP in general, play a
quantitative role in NADP+ to NADPH recycling and redox
balancing.
The importance of the NADPH-producing function of
the PPP has been corroborated in several studies mainly
addressing the antioxidant function of this coenzyme in
yeast and mammalian cells. As NADPH is required as a
redox equivalent in the antioxidant machinery, involving the
thioredoxin/peroxiredoxin and glutathione systems (Pollak,
Do¨lle & Ziegler, 2007a; Grant, 2008), yeast and mammalian
cells deficient for G6PDH become hypersensitive to several
oxidants (Juhnke et al., 1996; Gorsich et al., 2006; Kru¨ger
et al., 2011).
Which proportion of the cytoplasmic NADPH pool is
derived from the PPP? It varies, as the activity of the
oxidative PPP is flexibly regulated, and as discussed in
Section III , is actively increased during stress situations.
A flexible flux of the PPP is supported from studies
of NADPH-consuming enzymes, metabolic flux analysis,
but in particular by investigations on the oxidative stress
response. An illustrative example concerns the yeast NADPH
oxidase YNO1, a recently discovered enzyme that similar to
mammalian NADPH oxidases, oxidizes NADPH to produce
superoxide. When YNO1 is overexpressed in wild-type cells,
superoxide levels increase 10-fold. An increase in superoxide
levels is however no longer observed upon deletion of
zwf1, indicating that the oxidative PPP compensates for
the increased NADPH consumption caused by the YNO1
overexpression (Rinnerthaler et al., 2012).
Yeast cells deficient in NADPH production due to zwf1
deletion have an almost normal NADPH/NADP+ ratio
when growing exponentially and in glucose media. Their
NADPH/NADP+ ratio however collapses when exposed to
oxidants (Castegna et al., 2011). Thus, the contribution of
the oxidative PPP to the cellular NADPH pool is dynamic
and context dependent, and essential for most cell types only
when the NADPH requirement is increased. In Section IV
we discuss mechanisms that facilitate a dynamic control
of PPP activity under different physiological conditions,
which is achieved through cooperation of transcriptional
regulation, post-translational modifications, and allosteric
control (feedback and feedforward regulation) of the involved
enzymes.
In mammalian cells, G6PDH was intensively studied
because partial deficiency in this enzyme represents the most
common human enzyme defect, and as described in Section
VI, has severe haematological consequences (haemolytic
anaemia). A full depletion of G6PDH in mammals and
nematodes is however lethal at the organism level (embryonic
lethality) (Longo et al., 2002; Ying, 2007) while the same
mutation is tolerated at the cellular level (Pandolfi et al., 1995).
Similar to yeast cells, mouse embryonic stem cells possessing a
mutation leading to a strong reduction in G6PDH activity are
able to grow but are sensitive to externally applied oxidative
stress (Pandolfi et al., 1995; Filosa et al., 2003). Also, mouse
fibroblasts carrying a permanent deletion of the G6PDH
exon are viable, despite their low clonogenicity (Filosa et al.,
2003).
(a) Non-PPP sources of NADP(H)
The role of the PPP in providing NADPH has to be seen
in the context of other NADPH oxidoreductases, cellular
compartmentalisation and the NAD(H)/NADP(H) de novo
synthesis pathways. In many cell types and most conditions,
NADP(H) is present mostly in its reduced form (Ying, 2007;
Pollak et al., 2007a). However, this assumption has a degree
of uncertainty.
As membranes are considered to be NADPH imperme-
able, the NADPH recycling process and de novo biosynthesis
is compartment-specific (Ying, 2007; Pollak, Niere & Ziegler,
2007b). Hence, in most organisms the PPP contributes mainly
to the cytoplasmic NADPH pool. In mammalian mature ery-
throcytes which have no nucleus and no mitochondria, the
PPP is generally assumed to be the dominating source of this
coenzyme. In other cell types, there are important additional
cytoplasmic enzymes that contribute to the NADPH pool,
including the cytosolic isoforms of isocitrate dehydrogenase,
glutamate dehydrogenase, methylene-tetrahydrofolate
dehydrogenase, formyl-tetrahydrofolate dehydrogenase,
aldehyde dehydrogenase and malic enzyme (Bernt &
Bergmeyer, 1974; Wermuth, Mu¨nch & von Wartburg,
1977; Scheibe, 1987; Lee et al., 2002; Fan et al., 2014).
Another source influencing the NADPH level in mam-
malian cells, for instance in mitochondria, appears to
be trans-hydrogenation between NADH and NADP+,
forming NAD+ and NADPH (Jackson, 2003; Venditti,
Napolitano & Di Meo, 2013). The enzyme catalysing this
reaction, nicotinamide nucleotide trans-hydrogenase, is an
energy-driven integral protein of the inner mitochondrial
membrane, and required in mitochondria to maintain their
high NADPH/NADP+ ratio (Ronchi et al., 2013).
Finally, in the debate about NADPH sources its de novo
synthesis is less often taken into account. The synthesis of
NADPH de novo is achieved by phosphorylation of NAD(H)
by NAD kinase enzymes (Bieganowski et al., 2006; Pollak
et al., 2007a). The lack of an NADP(H) phosphatase in many
organisms implies that the de novo synthesis might primarily
be used for the initial synthesis of the NADP(H) molecules,
and not necessarily for controlling the NADP+/NADPH
balance. Nonetheless it remains plausible that certain cells
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might be able to compensate for a lack of NADPH by de novo
synthesis of the reduced form by phosphorylation of NADH.
(b) The synthesis of ribulose 5-phosphate in the non-oxidative PPP
The pentose phosphate pathway in yeast and mammals
shares much with the most important carbon assimilatory
pathway in plants, the Calvin cycle. Reverse flux through the
complete PPP could in theory assimilate carbon in a cyclic
manner. The problem is that certain reactions of the oxida-
tive PPP are not readily reversible. Accordingly, the Calvin
cycle bypasses these reactions via ribulose 1,5-bisphosphate
carboxylase oxygenase (Rubisco), apparently the most
abundant metabolic enzyme in the biosphere (Raines, 2003).
Rubisco converts ribulose 1,5-bisphosphate plus carbon
dioxide into two molecules of 3-phosphoglycerate. While
this enzyme is not shared with the PPP, other Calvin cycle
reactions are (Fig. 2).
In particular, both the non-oxidative PPP and the Calvin
cycle interconvert a total of 15 pentose carbon atoms
(contained in ribulose 5-phosphate) with 15 glycolytic
carbon atoms (in the form of fructose 6-phosphate and glyc-
eraldehyde 3-phosphate), sharing some important reactions.
However, while the classical non-oxidative PPP uses TAL
to make sedoheptulose 7-phosphate, the Calvin cycle uses
the glycolytic enzyme fructose-bisphosphate aldolase (FBA)
to convert erythrose 4-phosphate plus dihydroxyacetone
phosphate into sedoheptulose 1,7-bisphosphate, which
in turn is hydrolysed by the enzyme SH17BPase to
yield sedoheptulose 7-phosphate. This hydrolysis step
provides the thermodynamic driving force, pushing the
Calvin cycle towards ribulose 5-phosphate. Thus, while
the non-oxidative PPP is reversible, the Calvin cycle
is not.
Because FBA is a ubiquitous enzyme (playing an essential
role in glycolysis and gluconeogenesis, and also producing
sedoheptulose 1,7-bisphosphate), the distinguishing enzyme
of the Calvin cycle’s path from triose phosphates to pentose
phosphates is SH17BPase. Until recently, this enzymatic
activity was thought to be specific to photosynthetic organ-
isms. Metabolomic screening of yeast strains lacking genes of
unknown function, however, revealed a strain with elevated
sedoheptulose 1,7-bisphosphate. The associated gene was
subsequently shown to encode an enzyme with SH17BPase
activity involved in a novel variant of the non-oxidative
PPP that follows yet more closely the Calvin cycle reaction
sequences (Clasquin et al., 2011). This thermodynamically
driven variant of the non-oxidative PPP is termed ribo-
neogenesis. Just as gluconeogenesis uses the energy of
a sugar phosphate bond to convert trioses into hexoses,
riboneogenesis uses one to drive flux from trioses to pentoses.
Ribose 5-phosphate biosynthesis via riboneogenesis is
useful when demand for ribose exceeds that for NADPH.
In such cases it is presumably advantageous to have a
thermodynamically driven alternative to the standard
non-oxidative PPP, and to avoid an over-reduction of the
NADPH pool. Evidence for this effect was provided by
experiments in yeast (Clasquin et al., 2011). The cells were fed
with glucose labelled selectively at the 6-position with carbon
13 (6-13C-glucose). Such glucose produces doubly labelled
sedoheptulose 7-phosphate selectively via SH17BPase. This
labelling pattern was observed preferentially when yeast cells
were grown on media that decreased their need for NADPH
(e.g. by providing them with lipids). One can envision
the possibility that growing mammalian cells, including
cancer cells, could also in some circumstances need ribose
5-phosphate in excess of NADPH, i.e. when DNA and
RNA nucleotide synthesis is maximized (Ferreira, 2010;
Cairns et al., 2011). So far, however, has not been observed
in doubly labelled sedoheptulose 7-phosphate 6-13C-glucose
in mammalian cells (J. D. Rabinowitz, unpublished results).
Thus, SH17BPase activity plays a role in plant and microbial
metabolism, but not necessarily in animals.
In mammalian cells, a different additional influx into
the sedoheptulose 7-phosphate PPP has been discovered
recently: SHPK. This enzyme was identified based on the
observation that several patients suffering from nephropathic
cystinosis (CTNS) possess elevated urinary concentrations
of sedoheptulose. In these patients, the CTNS gene was
lost due to a 57 kb deletion, which aside from the CTNS
gene also contained a gene encoding for a carbohydrate
kinase-like (CARKL) protein. Biochemical assays have
then shown that CARKL is in fact a sedoheptulokinase
(SHPK) and catalyses the ATP-dependent phosphorylation
of sedoheptulose (Kardon et al., 2008; Wamelink et al.,
2008b). Apparently, the existence of SHPK implies that
mammalian cells are able to convert sedoheptulose, and
thus non-phosphorylated sugars, into ribose 5-phosphate
and glycolytic intermediates. The role of SHPK could be to
prevent an accumulation of sedoheptulose and related sugars
in the clearance of polyol metabolites (Kardon et al., 2008;
Wamelink, Struys & Jakobs, 2008a). Moreover, expressing
this gene in yeast increased H2O2-resistance, indicating that
a second biological role of SHPK could consist of providing
an increase of the PPP flux during the oxidative stress (Kru¨ger
et al., 2011). Finally, as discussed in Section VII, SHPK could
also ‘report’ altered metabolism to the immune system;
expression of this gene directs macrophage polarization
through control of glucose metabolism (Haschemi et al.,
2012).
III. THE GLYCOLYSIS/PPP TRANSITION:
METABOLIC AND TRANSCRIPTIONAL
MECHANISMS THAT CHANGE PPP FLUX UPON
DEMAND
The survival of a cell in its ever-changing environment
depends on the robustness, interconnection and functionality
of its biological networks. These are highly dynamic
and respond to changing endogenous and exogenous
conditions by interactions of a specific and limited set
of components (Ihmels, Levy & Barkai, 2004; Ralser
et al., 2007; Chechik et al., 2008; Buescher et al., 2010;
Fendt et al., 2010; Gru¨ning, Lehrach & Ralser, 2010).
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Fig. 2. The light-independent reactions of carbon fixation in the Calvin cycle share enzymes and reactions with the pentose phosphate
pathway (PPP) and glycolysis. Abbreviations are defined in Table 1; PGK, phosphoglycerate kinase; PRK, phosphoribulokinase,
TK, transketolase; FBA, fructose-bisphosphate aldolase.
Such dynamic activity is particularly relevant for the
metabolic network, where a few hundred metabolites
are interconnected through biochemical reactions within
metabolic modules, providing energy and biomolecules
depending on substrate availabilities, enzyme activities and
cellular demands. Therefore, to ensure proper functionality
of the metabolic network upon environmental changes,
metabolism is adapted. These adaptations involve the
production of increased amounts of components needed
and decreased concentrations of those unneeded, to save
resources and energy simultaneously, and importantly,
maintain homeostasis and prevent a collapse of the
metabolic network. Moreover, these reconfigurations are
highly regulated ensuring that concentrations of general
cofactor metabolites, such as NAD(H), NADP(H) and A(T)P
are not falling to fatal levels, the flux of the metabolic
network is stabilized, and enzyme activity and abundance of
the metabolic module is adjusted (Ihmels et al., 2004; Patil &
Nielsen, 2005; Cakir et al., 2006; Ralser et al., 2009; Gru¨ning
et al., 2010; Heinemann & Sauer, 2010).
(1) Regulation of the PPP during the oxidative
stress response
A paradigm example to study the rapid metabolic as well
as transcriptional regulation of the metabolic network is the
response of the PPP to oxidative stress. As aforementioned, in
yeast the NADPH-producing role of G6PDH is compensated
by other NADP-oxidizing enzymes under normal growth
conditions. However the NADP+/NADPH ratio collapses
upon a hydrogen peroxide (H2O2) exposure, rendering
G6PDH null cells highly oxidant sensitive (Nogae &
Johnston, 1990; Todisco et al., 2006; Castegna et al., 2010).
Indeed, the activity of the PPP is rapidly augmented when
cells are exposed to the oxidant. To induce this metabolic
transition, metabolic and gene regulatory mechanisms
cooperate (Fig. 3). In the first seconds upon an oxidative
burst, enzymes of glycolysis, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Ralser et al., 2007) and pyruvate
kinase (PK) (Anastasiou et al., 2011; Gru¨ning et al., 2011) are
inactivated causing a block in glycolysis, while the flux of
the PPP continues (Shenton & Grant, 2003; Ralser et al.,
2007; Ralser et al., 2009). This rapid response lasts a few
seconds to minutes, then transcriptional responses take over
and maintain higher PPP activity through up-regulation
of enzymes and post-translational modifications, including
those which increase the activity of G6PDH (Chechik et al.,
2008; Ralser et al., 2009; Cosentino, Grieco & Costanzo,
2011; Wang et al., 2014). This tight regulation seems to
have a dual role. During normal growth, it prevents an
overproduction of NADPH and PPP intermediates, and
minimizes carbon depletion due to CO2 production. At the
same time, it facilitates a rapid cellular response when stress
conditions apply (Shenton & Grant, 2003; Ralser et al., 2007;
Ralser et al., 2009; Grant, 2008).
The temporal inhibition of glycolysis to the benefit
of the PPP flux appears to be dependent on different
mechanisms. GAPDH for instance is rapidly inactivated by
chemical oxidation which correlates well with a boost in PPP
metabolite concentrations observed within a few seconds
(Ralser et al., 2007; Ralser et al., 2009). Other mechanisms
that support the inhibition of glycolytic enzymes concerns
allosteric control. A higher activity of the PPP is maintained
by feedback inhibition of triosephosphate isomerase (TPI)
by the glycolytic intermediate phosphoenolpyruvate (PEP)
(Gru¨ning et al., 2014). PEP is the substrate of pyruvate kinase,
that itself is controlled allosterically (Lyssiotis et al., 2012;
Morgan et al., 2013). A third strategy that facilitates rapid
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Fig. 3. Induction of the glycolysis/pentose phosphate
pathway (PPP) transition during oxidative stress. The PPP
plays a pivotal role in counteracting oxidative stress and is
implicated in (i) maintaining metabolic and redox homeostasis
via NADP+ to NADPH reduction, (ii) by synthesizing ribose
5-phosphate used in nucleotide biosynthesis (increased synthesis
is required upon DNA damage stress), and (iii) an important
role in activating stress-responsive gene expression. In a stress
situation, activity of the PPP is increased through orchestrated
allosteric/post-translational (=metabolic) and transcriptional
regulation, but these are not necessarily acting at the same
time. The fastest response (∼seconds timescale) is made
possible through oxidative inhibition of glycolytic enzymes
represented by the arrow moving from glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (illustrated as a
crystallographic structure), which acts as one of the metabolic
switches, while the PPP remains active. This process is
supported by post-translational modifications that increase
glucose 6-phosphate dehydrogenase (G6PDH) activity. The
comparatively slower (=minutes) process of altering transcript
and protein levels allows for cellular adaptation to stress in the
long(er)-term response. The GAPDH crystallographic structure
was obtained from RCSB-PDB (www.rcsb.org). PDB ID 3PYM:
(DOI:10.2210/pdb3pym/pdb).
PPP activation appear to be post-translational modifications
which affect the activity of G6PDH. In mammalian and
Xenopus laevis cells phosphorylation and acetylation increase
G6PDH activity during the stress response, so that this
enzyme does not become rate limiting (Cosentino et al.,
2011; Wang et al., 2014).
The glycolytic/PPP transition during oxidative stress
is mechanistically related to steady-state adaptation to
physiological conditions that are associated with increased
reactive oxygen species (ROS) production. Here, PK and its
feedback regulatory function on TPI and other metabolic
enzymes play a crucial regulatory role. In budding yeast, the
activity of PK is reduced when cells respire at high rate, and
less active isoforms (i.e. PKM2 in mammals, PYK2 in yeast)
are expressed. The resultant accumulation of PEP causes
feedback inhibition of several glycolytic enzymes, including
the redox regulator TPI, and flux in the PPP increases
(Gru¨ning et al., 2011; Gru¨ning et al., 2014). TPI inhibition by
PEP was required to prevent oxidative stress and oxidative
damage, and led to protein oxidation and mitochondrial
damage in respiring cells when interrupted (Gru¨ning et al.,
2011; Gru¨ning et al., 2014). As described in Section VIII,
a similar mechanism appears to be used by cancer cells to
maintain their metabolic redox balance as well.
(2) Transcriptional regulators of the PPP
The concerted allosteric/post-translational response is
followed by transcriptional events and transcripts and
proteins of the PPP increase in concentration (Chechik
et al., 2008). The transcriptional changes occur in a fully
coordinated manner, and enzymes are subsequently induced
depending on their molecular function (Ihmels et al., 2004;
Chechik et al., 2008). Therefore, the strictly timed program
facilitates the cell’s reaction against minatory redox collapse
immediately via the metabolome and the proteome, then
later via the transcriptome, to adapt to the cellular responsi-
bilities (Fig. 3). Such transcriptional patterns shape metabolic
network gene regulation in response to changing conditions
due to co-expression of enzymes that catalyse connected
reactions.
The details of transcriptional regulation of PPP enzymes
varies strongly among organisms; therefore, only principal
mechanisms will be discussed here. Both in mouse and yeast,
G6PDH is transcriptionally induced upon oxidative stress,
and by the need for NADPH and PPP intermediates for
anabolic reactions such as lipid synthesis and nucleotide
synthesis (Kletzien, Harris & Foellmi, 1994; Lee et al., 1999;
Stanton, 2012). These effects are not specific to G6PDH,
other PPP enzymes are dependent on transcriptional
mechanisms as well (Kletzien et al., 1994; Lee et al.,
1999; Stanton, 2012). This transcriptional regulators differs
according to the specific demands of the cell or tissue.
For instance, PPP regulation for lipid synthesis is achieved
by the sterol regulatory element-binding proteins (SREBPs)
class transcription factors, whereas the regulation during
oxidative stress is mediated by nuclear respiratory factor
2 (Nrf 2)-family and other transcription factors. The latter
also govern synthesis of many enzymes directly involved in
oxidative stress defence (Stanton, 2012). In budding yeast,
PPP gene expression control during oxidative stress is also
exerted by basic leucine zipper (bZIP, Yap1) transcription
factors and the nuclear response regulator Skn7. These
factors, acting either in concert or as single regulators,
govern the cellular response not only to oxidative stress,
but also when anabolic intermediates are needed (Lee et al.,
1999). During oxidative stress, another regulatory role has
been attributed to the transcription factor Sin Three Binding
protein 5 (Stb5), which activates PPP enzymes in response
to exposure to the thiol oxidizing agent diamide (Akache,
Wu & Turcotte, 2001; Larochelle et al., 2006; Hector
et al., 2009).
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
The pentose phosphate pathway 937
(3) Feedforward regulation of the metabolome to
the transcriptome: PPP metabolites as regulators of
the stress response
During stress conditions, the PPP seems to have attained
another role: the induction of stress-responsive gene
expression. Evidence for an NADPH-independent function
of the PPP in the antioxidant response comes from the
observation that enzyme deficiencies of both PPP branches
are oxidant sensitive (Juhnke et al., 1996; Kru¨ger et al., 2011).
Moreover, a yeast double mutant deleted for G6PDH (Zwf1)
and the non-oxidative PPP enzyme Tal1 is more H2O2
sensitive than the parent mutants deleted for either Tal1
or Zwf1 alone (Kru¨ger et al., 2011). By contrast, increased
oxidant resistance was obtained when the metabolite load of
the non-oxidative pathway was augmented due to expression
of the mammalian SHPK in yeast (Kardon et al., 2008;
Kru¨ger et al., 2011). In addition, stress response genes were
induced when the flux of the PPP was stimulated by genetic
perturbation of glycolysis (Kru¨ger et al., 2011). Finally, tuning
the NADPH demand gradually by overexpression of an
engineered NADPH-dependent butanediol dehydrogenase
led to a concomitant accumulation of PPP metabolites and
also triggered the induction of PPP and stress response
genes (Celton et al., 2012). Hence, during the stress response,
the PPP appears to play not only the role of a canonical
metabolic pathway which responds to oxidant treatments, but
also functions as a transcriptional balancer and is involved
in inducing components of the oxidative stress response. The
exact underlying molecular mechanisms are however yet
unknown.
IV. ANALYTICAL METHODS FOR
MEASUREMENT OF PPP INTERMEDIATES
Key to finding new PPP reactions, as well as elucidating reg-
ulation of the pathway, are reliable methods to quantify PPP
flux and intermediate concentrations. Major challenges of
studying the PPP include the high turnover rates of its inter-
mediates in the second or sub-second time range (Weibel,
Mor & Fiechter, 1974; De Koning & van Dam, 1992;
Douma et al., 2010) and low abundances of these compounds
(Casazza & Veech, 1986). Rapid sampling techniques such
as cold methanol quenching are typically employed to arrest
metabolism immediately in cells (De Koning & van Dam,
1992). A further difficulty in sugar phosphate analytics is the
proper separation of pentose isomers (ribose 5-phosphate ,
ribulose 5-phosphate and xylulose-5-phosphate) and hexose
isomers (glucose 6-phosphate, fructose 6-phosphate and
other relevant hexose monophosphates).
(1) From historical techniques to LC-MS/MS
A series of different methods have been developed to
study PPP metabolites and enzymes, including colorimetric
assays (Sable, 1952; Novello & McLean, 1968) and the
use of thin layer chromatography in combination with
14C-labelled substrates (Becker, 1976). Another widely
used quantification approach is to couple the enzymatic
interconversion of specific sugar phosphate substrates to the
NAD-dependent oxidation of glyceraldehyde 3-phosphate
by GAPDH, or other reactions catalysed by NADP(H)-
or NAD(H)-dependent enzymes, and to monitor the
consumption of NAD(P)H by spectrophotometric or
fluorometric methods (Sable, 1952; Kauffman et al., 1969;
Casazza & Veech, 1986; King, Passonneau & Veech, 1990).
However, these procedures are limited to measuring one
component at a time and are critically dependent on the
specificity of purified enzymes and optimal assay conditions.
Detailed studies of the PPP were therefore accompanied by
long, cumbersome analytical methods with relatively low
sensitivity and virtually no dynamic over time (Casazza &
Veech, 1986).
With the appearance of high-performance liquid chro-
matography (HPLC) these extensive measurement times
could be drastically reduced to 30–180 min (Giersch, 1979;
Smrcka & Jensen, 1988; Swezey, 1995), giving rise to major
advances in the field of PPP research. A combination of
chromatographic methods with mass spectrometry eventu-
ally facilitated the routine separation and analysis of sugar
phosphates. Several capillary electrophoresis-MS (Soga,
2007) and gas chromatography-MS methods (Koek et al.,
2006; Cipollina et al., 2009) have been developed; however,
they have already been relatively outnumbered by a number
of liquid chromatography tandem mass spectrometry
(LC-MS/MS) techniques for sugar phosphate measurement.
In a targeted LC-MS/MS approach, Wamelink et al., 2005
determined absolute concentrations of a series of sugar
phosphate intermediates by means of HPLC and tandem
mass spectrometry. Later, analogous methods were used
to measure extended sets of metabolites (Luo et al., 2007;
Buescher et al., 2010; Jannasch, Sedlak & Adamec, 2011;
Ru¨hl et al., 2012; Lu et al., 2010; Bajad et al., 2006). Without
doubt, mass spectrometry as the detection system has
strongly enhanced sugar phosphate analysis; but difficulties
in separating structural isomers still need to be overcome.
The development therefore of further powerful separation
procedures will be of high importance to allow for a more
reliable and robust quantification of PPP metabolites.
In addition to measuring metabolite levels, there has been
long-standing interest in measuring PPP flux. One classical
and reliable approach to measuring absolute oxPPP flux in
cells involves feeding, in separate experiments, 1-14C-glucose
and 6-14C-glucose and measuring radioactive CO2 release
(Katz & Wood, 1963). As carbon 1 of glucose is selectively
released by the oxPPP whereas other pathways metabolize
carbon 1 and 6 identically, the difference in radioactive CO2
release from these two tracers provides direct quantitation
of the oxPPP flux. Kinetic analysis of PPP intermediate
labeling from 13C-glucose by LC–MS can also be used to
calculate absolute oxPPP flux and gives similar estimates
to the 14C-CO2-release approach, but the 14C-approach
remains more precise (Fan et al., 2014).
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
938 A. Stincone and others
A strategy based on the cleavage of carbon 1 of glucose by
the oxPPP has also been employed to measure oxPPP relative
to non-oxPPP flux into ribose-5-phosphate. One method
involves feeding, separate experiments, 1-13C-glucose and
6-13C-glucose and measuring ribose-5-phosphate labeling
by mass spectrometry, with ribose-5-phosphate produced via
oxPPP labeled by 6-13C but not 1-13C-glucose. More conve-
niently, one can feed 1,2-13C-glucose and to look for singly
versus doubly labeled ribose-5-phosphate, with the former
made by the oxPPP and the latter by the non-oxPPP (Lee
et al., 1998). A limitation of these methods is that they do not
distinguish between net ribose production by the non-oxPPP
versus exchange flux (which can impact ribose-5-phosphate
labeling even if net non-oxPPP flux is away from ribose).
Thus, definitive methods for understanding non-oxPPP flux
are still needed, and additional tracers and measurement of
more metabolites’ labeling may, with proper computational
deconvolution, provide further insights (Brekke et al., 2012;
Tang et al., 2012; Crown et al., 2012).
In this vein, recent work has provided a new tracer
method for the PPP: Deuterium-labeled glucose (1-2H or
3-2H-glucose) to track specifically oxPPP-produced NADPH
and its subsequent utilization for reductive biosynthesis
(Fan et al., 2014; Lewis et al., 2014). Initial data show that
the oxPPP accounts for about 50% of total NADPH in
transformed mammalian cells growing in culture, with
most of this NADPH devoted to fatty acid synthesis. These
methods are now poised to quantitate variation in oxPPP
activity and NADPH usage across conditions, cell types, and
compartments.
(2) In vivo PPP measurements using NMR
MS-based methods are sensitive, selective and robust,
but are not applicable in vivo. Classic nuclear magnetic
resonance (NMR) methods regularly fall short of providing
the sensitivity required for studying the PPP. However,
recently, a new NMR technique has been introduced,
termed hyperpolarization, which can increase the sensitivity
of the 13C NMR experiment by more than 104-fold
(Ardenkjaer-Larsen et al., 2003). Being dynamic, this method
could be used to measure PPP flux in vivo. A 13C-labelled
cell substrate is mixed with a stable radical and cooled
to temperatures close to absolute zero (∼1 K) in a high
magnetic field (typically 3.5-5T). At this temperature the
electron spins in the radical are almost completely polarized.
This polarization is then transferred to the 13C spins
by microwave irradiation and the sample is then rapidly
warmed to room temperature with substantial retention of
the 13C spin polarization. Cells can then be exposed to the
hyperpolarized 13C-labelled substrate, or for in vivo studies
the tracer can be injected intravenously or added to the
growth media of microorganisms. The signal is now boosted
as a result of polarization of the 13C spins, so that the position
of the molecule and the metabolites formed from it can be
imaged (Brindle et al., 2011; Kurhanewicz et al., 2011).
The major limitation of the technique is the relatively
short life time of the spin polarization (typically ∼30 s in vivo),
which means that only relatively rapid metabolic processes
can be imaged and the experiment must be accomplished
within 2–5 min following injection of the hyperpolarized
substrate. Measurements with hyperpolarized [U-2H,
U-13C] glucose in E. coli, yeast and breast cancer cells have
shown production of hyperpolarized [1-13C] pyruvate or
lactate, which allows real-time measurements of glycolytic
flux (Meier, Jensen & Duus, 2011a; Meier et al., 2011b; Har-
ris, Degani & Frydman, 2013). The technique was recently
translated to a clinical study of prostate cancer (Nelson et al.,
2013), and as discussed in Section VIII, is revealing the
activity of the PPP in human cancer cell metabolism in vivo.
V. THE PPP IN BIOTECHNOLOGY: METABOLIC
ENGINEERING
The PPP is one of the most important targets for
metabolic engineering and biotechnology. One way
in which this pathway is utilized is as a source of
NADPH and pentose sugars for the overproduction of
various commercially and medically important com-
pounds such as carotenoids (Schwender et al., 1996; Mart
ínez et al., 2008), polymers (Kabir & Shimizu, 2003; Jung
et al., 2004), antibiotics (Jørgensen et al., 1995; Avignone
Rossa et al., 2002; Butler et al., 2002; Li & Townsend,
2006; Borodina et al., 2008), alcohols (Jeppsson et al., 2002;
Jeffries & Jin, 2004; Hahn-Ha¨gerdal et al., 2007), nucleosides
(Kamada et al., 2001) and amino acids (Marx et al., 1997;
Herrmann & Weaver, 1999). Additionally, altering the
PPP was used to prevent carbon exhaust during pentose
fermentation (Verho et al., 2002). Recently, the PPP has been
utilized to create a synthetic non-oxidative glycolysis/PPP
hybrid pathway able to produce energy significantly more
efficiently by precluding carbon loss via carbon dioxide
(Bogorad, Lin & Liao, 2013) – a proof of concept that
metabolic engineering could contribute to reducing the
current exhaust of greenhouse gases.
Focus on producing the biopolymer poly-hydro-
xybutyrate (PHB), a non-toxic biodegradable and
bio-derived ‘green’ plastic (Hankermeyer & Tjeerdema,
1999), has included modification of both the oxidative and
non-oxidative enzymes of the PPP. The insertion of gnd
and tktA genes (6PGDH and TKL, respectively) from E. coli
into the facultative chemolithoautotroph bacterium, Ralsto-
nia eutropha, amplified gnd, which overproduced NADPH,
but also suppressed growth as well as PHB production.
Conversely, amplification of tktA significantly increased the
generation of PHB via efficient conversion of glyceralde-
hyde 3-phosphate into acetyl-coenzymeA, the precursor for
PHB biosynthesis (Lee, Shin & Lee, 2003). Another attempt
focused on generating PHB via the PPP targeted the oxida-
tive pathway only. By deleting the pgi gene in E. coli, carbon
flux was shown to be redirected through the PPP in turn
increasing the production of NADPH, creating a reducing
power imbalance and affecting cell growth. The introduc-
tion of the NADPH-consuming PHB biosynthetic pathway
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into the pgi knockout, allowed partial cell growth recovery
(Kabir & Shimizu, 2003).
Another genus where modification of the PPP was suc-
cessful in industrial application is Streptomyces, a work-
horse for the generation of various antibiotics (Hopwood,
2007). To overproduce the pigmented antibiotics acti-
norhodin (ACT) and undecylprodigiosin (RED), the pfkA2
gene was deleted in S. coelicolor A3(2), leading to increased
flux through the PPP (Borodina et al., 2008). Similarly, inac-
tivation of the glycolytic genes gap1 and gap2, encoding
GAPDH, in S. clavuligerus was exploited to increase pro-
duction of clavulanic acid, a β-lactamase inhibitor, used
alongside penicillin and cephalosporin to combat antibi-
otic resistance (Li & Townsend, 2006). The overproduc-
tion of clavulanic acid was facilitated through increasing
the supply of its precursor glyceraldehyde 3-phosphate. A
recent study proposed that in order to increase the flux
towards the PPP, TAL overexpression would be much
more useful than GAPDH inactivation, because of the
compromised carbon balance of the PPP (Linck et al.,
2014).
Modification of the PPP has also been effective in
fungal biotechnology. The fungus Penicillium chrysogenum
was exploited by enhancing flux through the PPP to
increase NADPH levels, thereby increasing the penicillin
yield (Jørgensen et al., 1995). Other applications of the
PPP in fungal biotechnology include the optimisation
of alcohol, amino acids (e.g. lysine), nucleosides, inosine
and 5′-xanthylic acid production (Marx et al., 1997;
Kamada et al., 2001; Jeppsson et al., 2002; Overkamp et al.,
2002; Verho et al., 2002). Hence, in several instances
an altered PPP flux was beneficial for biotechnological
production cycles in both bacteria and yeast systems via
its NADPH donor function, or inhibited to decrease carbon
exhaustion. Thus, altering PPP activity is exploitable in
both microbial and eukaryotic biotechnology in order
to optimize cofactor- and sugar-phosphate-dependent
processes.
VI. INBORN ERRORS WITHIN PPP ENZYMES
THAT LEAD TO HUMANMETABOLIC DISEASE
Four known metabolic genetic diseases are the direct
consequence of a deficiency in a PPP enzyme; and at least
two genetic disorders associated with the PPP are attributed
to enzyme mutations in glycolysis via affecting PPP activity.
Notably, these PPP disorders encompass both the most
frequent human genetic defect (G6PDH deficiency) as well
as the so-far rarest human disorder [ribose 5-phosphate
isomerase (RPI) deficiency], where only a single patient
has been diagnosed to date. The other defects, TAL
deficiency, as well as the two glycolytic syndromes TPI
and glucose phosphate isomerase (GPI) deficiency, occur at
a different frequency but are considered rare disorders as
well (Fig. 4).
(1) G6PDH deficiency, the most common human
enzyme defect
G6PDH deficiency (OMIM: 305900) is an X-linked disorder;
the gene is located at the telomeric region of the long
arm of the X chromosome (band Xq28) (Cappellini &
Fiorelli, 2008; Van Zwieten, Verhoeven & Roos, 2014).
Prevalent in more than 400 million people worldwide, it
represents the most common heritable human enzyme defect
(Cappellini & Fiorelli, 2008; Nkhoma et al., 2009). The global
occurrence of G6PDH deficiency is geographically correlated
with areas inhabited by populations historically exposed to
endemic malaria, including Africa, Mediterranean Europe,
South-East Asia and Latin America (Ruwende & Hill, 1998).
The most frequent clinical manifestation is neonatal
hyperbilirubinaemia and chronic haemolytic anaemia
(Luzzatto & Mehta, 1995; Cappellini & Fiorelli, 2008; Van
Zwieten et al., 2014). The high frequency of the disorder
is likely explained as reduced G6PDH activity appears
protective against malaria caused by Plasmodium falciparum
(Luzzatto & Bienzle, 1979; Ruwende & Hill, 1998). As
the oxidative PPP is the only relevant NADPH source for
red blood cells, a decrease in NADPH production is likely
associated with the clinical phenotype, but potentially also
explains this anti-malaria advantage. As a consequence,
however, despite most carriers of mutant G6PDH alleles
being asymptomatic, exposure to oxidative stressors such as
artemisinin (and other drugs) or infections can elicit acute
haemolysis in G6PDH patients. As such, the epidemiology of
G6PDH deficiency has been related to the sickle cell anaemia
phenotype, caused by Hbs and SS variants of haemoglobin.
Sickle cell anaemia is associated with episodes of acute illness
and progressive organ damage, but is also associated with
heterozygous advantage against malaria (Rees, Williams &
Gladwin, 2010).
G6PDH deficiency can be associated with a second,
rare defect in the PPP, 6-phosphogluconate dehydrogenase
(6PGDH) deficiency (Beutler, Kuhl & Gelbart, 1985). The
first evidence of the enzyme deficiency was reported in
1963, when a female patient presenting G6PDH deficiency
exhibited reduced activity of 6PGD as well (Brewer & Dern,
1964). More recently, also G6PDH independent incidences
of this defect have been reported, and lead to reduced redox
tolerance of erythrocytes (Caprari et al., 2001).
(2) RPI deficiency, the currently rarest human
disorder
By contrast with G6PDH deficiency, other PPP disorders
are exceptionally rare. Huck et al., 2004 described a patient
with a deficiency of RPI (OMIM: 608611) who suffered
from leukoencephalopathy and peripheral neuropathy. This
patient had psychomotor retardation from early in childhood
and developed epilepsy at the age of four. From the age
of 7 the patient experienced neurological regression, with
deterioration of vision, speech, hand coordination, walking,
and seizures. Neurological examination at the age of 14 years
showed spasticity, bilateral optic atrophy, and nystagmus on
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
940 A. Stincone and others
Fig. 4. Inherited metabolic disease caused by pentose phosphate pathway (PPP) deficiencies, including two glycolytic
enzymopathies with effects on the PPP. PPP enzymopathies are caused either by complete or partial deficiency of PPP
and glycolytic enzymes. Abbreviations are defined in Table 1, H6PDH, hexose 6-phosphate dehydrogenase.
lateral gaze, an increased masseter reflex and mixed cerebel-
lar/pseudobulbar dysarthria. He had prominent cerebellar
ataxia and mild peripheral neuropathy and displayed severe
mental retardation. The patient is now (2014) in his twenties,
and so far a unique case, as since the original report no
further cases of RPI deficiency have been described.
The molecular diagnosis of the rare case of RPI deficiency
was facilitated through a combination of metabolic profiling
and candidate gene re-sequencing. Magnetic resonance
imaging (MRI) is able to identify brain abnormalities in
children with neurological deficits (Watkins, Gadian &
Vargha-Khadem, 1999; Huck et al., 2004). MRI of the
patient showed extensive anomalies of the cerebral white
matter with prominent involvement of the short association
fibres (U-fibres), relative sparing of periventricular white
matter, and complete sparing of corpus callosum and
internal capsule (Van der Knaap et al., 1999). Extremely
high concentrations of pentitol metabolites (arabitol and
ribitol) were found in the brain by magnetic resonance
spectroscopy (MRS), and in cerebrospinal fluid, plasma
and urine, as well as xylulose in the urine as tested by
mass spectrometry (Van der Knaap et al., 1999). These
metabolites can derive from PPP intermediates xylulose,
ribose 5-phosphate and ribulose 5-phosphate, which guided
to the identification of the candidate gene by targeted
re-sequencing of PPP enzymes. Two mutant alleles in
the RPI encoding RPIA gene were demonstrated: a 1 bp
deletion (540delG) resulting in a frameshift at codon 181
and a predicted truncated protein of 196 amino acids, and
a missense mutation C182T, resulting in an Ala-to-Val
substitution (A61V). The finding of two mutant alleles
in the patient with apparently healthy parents suggests
autosomal recessive inheritance. Genetic and biochemical
evidence suggests an explanation for the rareness of the
case: full RPI deficiency appears to be lethal. Studies
of patient-derived cell lines and transgenic yeast models
however revealed that the patient carried an uncommon
allelic combination: he is heterozygous for a catalytically
inactive RPI allele, whereas the second allele encodes a
partially catalytically functional enzyme that exhibits a
cell-type-dependent expression deficit in addition (Wamelink
et al., 2010).
(3) TAL deficiency
Transaldolase deficiency (TAL or TALDO deficiency,
OMIM: 606003) is caused by autosomal recessive deficiency
in the human TAL-encoding gene (TALDO1) located
on chromosome 11p15.5–p15.4, and has recently been
diagnosed in more than 30 patients worldwide (Wamelink
et al., 2007; Wamelink et al., 2008a; Tylki-Szyman´ska et al.,
2009; Balasubramaniam et al., 2011; Eyaid et al., 2013).
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TAL-deficient patients suffer from great phenotypic variabil-
ity. Most patients display first symptoms in the neonatal or
antenatal period, with prenatal intra-uterine growth retarda-
tion, oligohydramnios and hydrops foetalis being described
(Valayannopoulos et al., 2006). Newborns present with hep-
atosplenomegaly, bleeding diathesis, abnormal liver function,
cholestatic jaundice and elevated liver enzymes, while in
older patients, hepatic fibrosis or cirrhosis is the pathological
liver hallmark. Most patients show haemolytic anaemia,
dysmorphic features, neonatal oedema and congenital heart
defects. Moreover, renal manifestations and endocrine
disorders have been frequently reported (Loeffen et al., 2012).
Mild transient hypotonia was described in several patients
but mental and motor development was normal in most
patients. Recently, a TAL-deficient patient with early onset
hepatocellular carcinoma with an 9 years old asymptomatic
older brother were described (Leduc et al., 2013).
TAL deficiency results in the accumulation of seven-
carbon sugars (sedoheptulose, mannoheptulose), sedohep-
tulose 7-phosphate, and open chain sugar-alcohols (poly-
ols) including erythritol, arabitol, ribitol, sedoheptitol and
perseitol, and erythronic acid derived from the pathway
intermediates (Verhoeven et al., 2001; Wamelink et al., 2005;
Engelke et al., 2010) that can help as biomarkers in diag-
nosis. The clinical picture of TAL deficiency is dominated
by liver fibrosis/cirrhosis, resulting in permanent scar tissue.
Since TAL has been recognized as a regulator of apop-
totic signal-processing (Banki et al., 1996), this might have
relevance for the pathogenesis of liver disease, as observed
in patients and in TAL-deficient mice (Perl et al., 2011).
In addition, accumulation of the metabolite sedoheptulose
7-phosphate has been suggested to be involved in the patho-
physiology of liver cirrhosis (Verhoeven et al., 2001), and
could be functionally connected to the disease phenotype.
In a mouse model of TAL-deficiency, the accumu-
lation of sedoheptulose 7-phosphate and a failure to
recycle ribose 5-phosphate through the non-oxidative
branch has been observed. Furthermore, diminished
production of NADPH led to secondary depletion of
reduced glutathione (GSH) and oxidative stress, as well
as loss of the mitochondrial transmembrane poten-
tial and mitochondrial mass (Hanczko et al., 2009).
A decrease of NADPH was potentially caused by the conver-
sion of five-carbon sugar phosphates to five-carbon polyols by
aldose reductase at the expense of NADPH levels (Perl et al.,
2011). In some earlier diagnosed TAL-deficient patients, low
levels of cholesterol, estradiol, testosterone or vitamin D were
detected, indicating decreased NADPH/NADP+ and lead-
ing to decreased activity of NADPH-dependent reactions
(i.e. cholesterol biosynthesis, hormone metabolism) (Banki
et al., 1996). Haemolytic anaemia was also observed in most
patients, probably related to decreased NADPH production
in erythrocytes as observed in G6PDH deficiency.
(4) GPI deficiency
GPI catalyses the interconversion of glucose 6-
phosphate to fructose 6-phosphate. A deficiency in this
enzyme (OMIM: 613470) increases the flux in the PPP,
as the glycolytic route of carbon metabolism becomes inhib-
ited. Deficiency of erythrocyte GPI was first described in a
boy with lifelong nonspherocytic anaemia in 1968 (Baughan
et al., 1968). In a patient diagnosed in 1985, the GPI defi-
ciency syndrome was characterized by a deficiency in red
cells, granulocytes and muscles (Schro¨ter et al., 1985). In
1993, another case of GPI deficiency was associated with
hereditary nonspherocytic haemolytic anaemia (Shalev et al.,
1993). Mutations found in GPI deficiency retain residual
activity of the enzyme, but the deficient enzymes were char-
acterized by reduced thermostability (Kugler & Lakomek,
2000). The decreased activity of the isomerase causes an
increase in glucose 6-phosphate, erythrose 4-phosphate and
6-phosphogluconate, indicating increased metabolite load
and flux in the PPP.
In yeast cells grown on glucose, a full deficiency of GPI
is lethal, but can be complemented by the overexpression
of NADPH-oxidising enzymes. This indicates that the
fatality of a full GPI deficiency results from redox cofactor
imbalance due to NADPH overproduction in the PPP
(Verho et al., 2002).
(5) TPI deficiency
TPI deficiency (OMIM: 615512) was one of the first
enzymatic defects to be associated with the PPP. Schneider
et al., 1965 reported a deficiency of the enzyme in red blood
cells referring to the disorder as Dacie’s type II haemolytic
anaemia. TPI deficiency is further of historical importance
in the treatment of rare diseases, as it was an early case where
an enzyme replacement therapy was applied (Ationu et al.,
1999).
TPI deficiency is a rare and severe disease involving
nonspherocytic haemolytic anaemia, leading to pro-
gressive neuronal degeneration, muscle degeneration
and is associated with deadly infections and spasticity.
In most cases, the affected children die before adulthood
(Schneider, 2000; Orosz et al., 2009). Since the discovery of
the syndrome less than 100 patients have been diagnosed
worldwide (Schneider & Cohen-Solal, 1996). This frequency
is lower than the natural mutation rate would predict,
but also lower as predicted from the estimated population
frequencies of recessive TPI-deficient alleles. This indicates
that homozygously defective alleles are embryonically
lethal, a notion supported by studies in mice (Merkle &
Pretsch, 1989). The substantial frequencies of heterozygote
TPI deficiency lead to speculations of a heterozygous
advantage of TPI-deficient alleles (Mohrenweiser, 1981;
Mohrenweiser, Wurzinger & Neel, 1987; Watanabe, Zingg
& Mohrenweiser, 1996). In a more recent study, the entire
TPI locus was re-sequenced in 387 centenarians, and single
nucleotide polymorphisms (SNPs) were genotyped in an
even larger sample of long-lived individuals (N = 1422) and
younger controls (N = 967). However, no heterozygous TPI
deficient alleles were confirmed (Ralser et al., 2008). The
discrepancy could indicate that the observed differences in
TPI activity had an epigenetic or post-translational cause,
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or that high frequencies of heterozygous TPI null alleles are
a population-specific phenomenon.
Despite a substantial number of TPI-deficient alleles
having been described (Schneider & Cohen-Solal, 1996),
a single allele describes the majority of clinical cases. This
allele carries a mutation exchanging a glutamic acid residue
on position 105 (position 104 when not counting the ATG
codon), to an aspartic acid, located in the region of the TPI
enzyme responsible for dimer formation (Arya et al., 1997;
Schneider, 2000; Rodríguez-Almaza´n et al., 2008). This allele
has been the only one described to cause TPI deficiency in
the homozygous state, and it was speculated that the allele
may descend from a single individual that may have lived
in what is now France or England around 1000 years ago
(Arya et al., 1997). Recently, the same allele has also been
found in a Turkish family, but it is currently unclear whether
it results from a de novo mutation (Sarper et al., 2013). It has
been discovered in a transgenic yeast model expressing the
human isoform that this residue substantially interferes with
the dimerisation of TPI, but does not per se interfere with
catalysis (Ralser et al., 2006). The global structure of TPIE104D
is similar to that of the wild-type; however, residue 104 is part
of a conserved cavity that possesses an elaborate conserved
network of buried water molecules at the dimer interface
(Rodríguez-Almaza´n et al., 2008). In the TPIE104D mutant, a
disruption of contacts of the amino acid side chains in the
conserved cluster leads to a perturbation of the water network
in which the water–protein and water–water interactions
joining the two monomers are significantly weakened and
diminished (Rodríguez-Almaza´n et al., 2008). Hence, TPI
deficiency is primarily caused by a structural defect.
How does TPI deficiency, a disorder caused by a
structurally defective glycolytic enzyme, then relate to the
PPP? In the course of generating a yeast model for TPI
deficiency, it was discovered that TPI alleles with reduced
catalytic activity render cells resistant to oxidants (Ralser et al.,
2006). In yeast, this was mainly described for thiol-oxidizing
reagents such as diamide, however in Caenorhabditis elegans
sensitivity was observed also for natural oxidants including
juglone (Ralser et al., 2007). Cells expressing the mutant TPI
alleles possess increased concentration of PPP metabolites,
and the antioxidant effects of TPI mutant alleles are fully
dependent on the first enzyme of the oxidative PPP, G6PDH
(Ralser et al., 2007; Gru¨ning et al., 2011; Gru¨ning et al., 2014).
In Drosophila melanogaster, the situation seems to be more
complex and dependent on respiratory activity of the TPI
mutant cells. Also Drosophila melanogaster cells’ TPI mutations
affect oxidant resistance, however their redox status seem
to shift towards oxidation (Hrizo et al., 2013). Moreover,
as shown below (Section VIII), TPI mutant alleles were
important in understanding the role of the PPP’s antioxidant
activity in cancer.
(6) Hexose 6-phosphate dehydrogenase (H6PDH)
deficiency
H6PDH is a luminal enzyme analogous to G6PDH
responsible for NAD+ and NADP+ reduction in the
endoplasmic reticulum. The enzyme oxidizes glucose 6-
phosphate, glucose, galactose 6-phosphate and 2-
deoxyglucose 6-phosphate (Krczal, Ritter & Ko¨mpf, 1993;
Senesi et al., 2010). Several allelic variants of H6PDH muta-
tions are known and result in hirsutism, oligomenorrhoea,
obesity, acne and infertility (Jamieson et al., 1999; Draper
et al., 2003; Lavery et al., 2008). Draper et al., 2003 hypoth-
esized that mutations in H6PDH could cause an NADPH
deficiency in the endoplasmic reticulum (ER), affecting the
directionality of the 11-beta-hydroxysteroid dehydrogenase
type 1 (HSD11B1) reaction. HSD11B1 is a regulator of the
tissue-specific glucocorticoid availability in cortisone reduc-
tase deficiency (OMIM: 604931) (Draper et al., 2003). Indeed,
in a study conducted on four patients suffering from cortisone
reductase deficiency, four novel and one known mutations
in the H6PDH gene in homozygous or compound heterozy-
gous state were identified. Expression data on these mutations
revealed loss of H6PDH function (Lavery et al., 2008). Mouse
models carrying the H6PDH mutations develop fasting hypo-
glycaemia, increased insulin sensitivity and increased basal
and insulin-stimulated glucose uptake (Lavery et al., 2008).
It was observed that cortisol reductase deficiency presents
a similar phenotype to polycystic ovary syndrome (POS).
Furthermore, the H6PDH gene was associated with multiple
sclerosis (Alcina et al., 2010).
VII. HOST–PATHOGEN INTERACTIONS: THE
ROLE OF THE PPP IN INFECTIOUS DISEASE
(1) The PPP as a target in parasitic protozoa
Protozoan parasites are responsible for a considerable
number of debilitating infections that affect a significant
number of people around the world, most commonly in
developing countries. These protozoa include the kinetoplas-
tids Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp.
These parasitic protozoa cause sleeping sickness, Chagas’
disease and leishmaniasis (cutaneous, visceral and mucosal),
respectively. Various species of the Aconoidasida genus
Plasmodium are responsible for malaria, while the archeamoe-
ban (amitochondriate) parasite Entamoeba histolytica is the
causative agent of amoebiasis, a disease characterized by
diarrhoea (amoebic colitis) or abscesses principally of the
liver. The biology behind the host–parasite relationship, the
infection process and in some cases, even to identify drug
targets, is highly dependent on parasite metabolism. Parasite
metabolic reconfiguration and mutations in their enzymes
may contribute towards resistance to drug treatment as well
as parasite evasion of the host innate immune response. One
important way the host immune system counteracts parasite
infection is via the generation of hydrogen peroxide and
other oxidants. Due to its function in maintaining the supply
of the antioxidant cofactor NADPH, the PPP is therefore
of great importance to the pathology of these parasites,
becoming an attractive target for drug design.
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(a) Kinetoplastids, the trypanothione pathway and the
compartmentalization of the PPP in glycosomes
Kinetoplastids have a complete and functional PPP. Studies
in both T. cruzi (Igoillo-Esteve et al., 2007) and Leishmania
mexicana (Maugeri et al., 2003) have shown that the PPP
metabolized 5–10% of total glucose. Most of the canonical
PPP enzymes have homologues in these parasites and have
been cloned, characterized and crystallized in at least
one of the trypanosomatids (Fig. 5A) (Barrett et al., 1994;
Phillips et al., 1998; Duffieux et al., 2000; Veitch et al., 2004;
Igoillo-Esteve & Cazzulo, 2006; Stern et al., 2007; Stoffel
et al., 2011; Kaur et al., 2012). Exceptions include TAL and
RPE, for which less information is available (Cronín, Nolan
& Voorheis, 1989; Igoillo-Esteve et al., 2007). However, these
PPP enzymes could be important for the infection process.
It has been observed that bloodstream forms (host stage) in
T. brucei have neither TKL nor RPE activities; hence, at
this stage, they are not capable of forming glyceraldehyde
3-phosphate from the non-oxidative branch of the PPP
(Cronín et al., 1989).
The enzymes of the PPP in these parasites are mainly
cytosolic. However, they have also been allocated to the
glycosome, the trypanosomatids’ peroxisome, that contains
the major part of the glycolytic pathway (Hannaert et al.,
2003). The role of the PPP enzymes in the glycosome appears
to be: (i) the exchange of intermediates with the glycolytic
pathway; (ii) the supply of ribose 5-phosphate for nucleotide
biosynthesis, which also occurs in the glycosome; and (iii) the
supply of NADPH for the antioxidant system (trypanothione
reductase) that has also been detected in the glycosome
(Hannaert et al., 2003). In turn, one of the main functions
of the PPP in the cytosol is the supply of reducing power
(NADPH) to the antioxidant system. In the trypanosome,
antioxidant action relies on an alternative molecule,
trypanothione [T(SH)2; N1-N8-bisglutathionylspermidine],
an analogue of glutathione. Together with its reducing
enzyme trypanothione reductase (TryR), trypanothione
replaces all the functions that the system glutathione
(GSH)/glutathione reductase (GR) has in other cells
(Olin-Sandoval, Moreno-Sa´nchez & Saavedra, 2010). The
major part of the antioxidant system in trypanosomatids
therefore depends on trypanothione, and its reduction
requires NADPH equivalents supplied by the PPP (Barrett,
1997). Due to the central role of the PPP in antioxidant
metabolism, several studies have focused on the regulation
of PPP enzymes under oxidative stress. It has been
demonstrated that G6PDH increases its activity 46-fold
in metacyclic trypomastigotes of T. cruzi (infective form)
exposed to 70 μM H2O2, an increase related to an
increment in protein content. By contrast, epimastigotes
(insect form) exposed to 20 μM of H2O2 had decreased
G6PDH activity and protein content, an observation which
can be explained with the reasoning that under physiological
conditions, epimastigotes are not exposed to oxidative stress
(Igoillo-Esteve & Cazzulo, 2006). These results demonstrate
that oxidative stress not only regulates the activity of G6PDH
kinetically but also at the protein level.
RNAi-mediated knock-down of G6PDH in bloodstream
forms of T. brucei promoted a negative effect on parasite
growth, suggesting an essential function for this enzyme
(Cordeiro, Thiemann & Michels, 2009). This PPP enzyme
appears to be associated with the antioxidant machinery
of the parasite T. brucei partially depleted of G6PDH are
sensitive to H2O2 (Gupta et al., 2011). Moreover, PPP
flux in Leishmania mexicana increases when the parasites
are exposed to methylene blue causing oxidative stress,
providing further support that the PPP is highly essential in
these parasites’ response to oxidative conditions (Maugeri
et al., 2003). The importance of the PPP in the response to
oxidative stress in trypanosomes has also been corroborated
by dynamic modelling. Recently, a kinetic model of
glycolysis in Trypanosoma brucei (Albert et al., 2005; Achcar
et al., 2012) was extended with PPP reactions (Kerkhoven
et al., 2013). Both models predicted that the flux through
the cytosolic PPP was regulated by oxidative stress.
Under low-oxidative-stress conditions the flux through
this pathway was very low. However, the simulation of
oxidative stress promoted an increase in the flux through
glucose 6-phosphate dehydrogenase/hexose 6-phosphate
dehydrogenase, 6-phosphogluconolactonase (PGL) and
ribose 5-phosphate isomerase (RPI) of about seven-, 5.5-
and 4-fold, respectively. After the stress, a steady state was
predicted to be reached after 1 min (Kerkhoven et al., 2013).
6PGDH in T. brucei is essential (Barrett, 1997; Kerkhoven
et al., 2013). The lethal phenotype has been attributed to the
accumulation of 6-phosphogluconate inhibiting PGI (Barrett,
1997), a result that has been challenged by (i) the observation
that fructose supplementation, which enters glycolysis after
PGI, does not rescue the cells from death, and (ii) a lack of
support from dynamic modelling (Kerkhoven et al., 2013).
Mutations in TKL (null mutants), by contrast, do
not have any effect on cell growth, nor were changes
in morphology detected (Stoffel et al., 2011). Metabolite
analysis of these mutants showed that the substrates ribulose
5-phosphate, ribose 5-phosphate and xylulose 5-phosphate
had accumulated 7.9-fold with a concomitant decline
in the product sedoheptulose 7-phosphate. Additionally,
intracellular concentration of 2,3-bisphosphoglycerate, phos-
phoenolpyruvate, fructose 6-phosphate and glyceraldehyde
3-phosphate were reduced 2-, 4.5-, 1.5- and 3.2-fold, respec-
tively (Stoffel et al., 2011). Consequently, taken together, these
results indicate that a main role of the PPP in trypanosomatids
appears to be in defence against oxidative stress.
(b) Plasmodium spp.
Plasmodium spp. parasites possess a complete and functional
PPP (Preuss, Jortzik & Becker, 2012). This has been
confirmed through in silico analysis, using transcriptome
profiles collected hourly during the intra-erythrocytic cycle
of the parasite. Both branches of PPP are active at least
at 50 hours post-invasion of the erythrocyte and their
expression varies most likely due to cell requirements,
such as ribonucleotide synthesis or NADPH and ATP
demand (Bozdech & Ginsburg, 2005). The canonical PPP
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Fig. 5. The pentose phosphate pathway (PPP) in parasitic protozoa (left) and bacterial infection (right). In kinetoplastids (A),
PPP enzymes are localised in the cytosol and glycosomes (*). Plasmodia (B) have a bifunctional enzyme (glucose 6-phosphate
dehydrogenase 6-phosphogluconolactonase; GluPho) that has the activity of glucose 6-phosphate dehydrogenase (G6PDH) and
6-phosphogluconolactonase (6PGL). Entamoeba histolytica lacks G6PDH and transaldolase (TAL), however has developed an
alternative hexose–pentose interconversion pathway (C) in which the enzymes transketolase (TKL), fructose-bisphopshate aldolase
(FBA) and pyrophosphate dependent-phosphofructokinase [(PPi)PFK] are involved. The activity of the PPP pathway is modulated
by metabolites that respond to oxidants (i.e. H2O2 or paraquat); oxidant-responsive enzymes; or by the glutathione/glutathione
disulfide (GSH/GSSG) ratio. 6PGDH, 6-phosphogluconate dehydrogenase. During bacterial lipopolysaccharide (LPS) infection of
the mammalian intestine, sedoheptulokinase (SHPK) is of reduced activity in the host (D) and leads to macrophage M1 polarization.
In bacteria (E), sedoheptulose 7-phosphate isomerase (SHI) and arabinose 5-phosphate isomerase (API) enzymes can increase LPS
production. O2−: superoxide.
enzymes such as TKL and RPI have been cloned and
characterized in P. falciparum (Holmes et al., 2006; Joshi
et al., 2008). Interestingly, Plasmodium spp. possess fusion
enzymes within the PPP. One well-studied example is
a protein that combines G6PDH and 6PGL activities
in a single enzyme, glucose 6-phosphate dehydrogenase
6-phosphogluconolactonase (GluPho) (Fig. 5B). This enzyme
is regulated by S-gluthathionylation, suggesting that the
glutathione/ glutathione disulfide (GSH/GSSG) ratio
regulates GluPho activity (Jortzik et al., 2011). The fusion
protein is not the exception, and multiple independent
fusions of G6PDH with other PPP enzymes have been
found in this plasmodial parasite, indicating that pathway
efficiency is potentially increased by channelling metabolites
in this manner (Stover, Dixon & Cavalcanti, 2011).
Plasmodial parasites are continuously exposed to oxidative
stress during the life-cycle stage in the erythrocyte; as they
take haemoglobin into their acid food vacuole, Fe2+ is
oxidised to Fe3+ and superoxide anions are produced,
which in turn promote the formation of H2O2 and
hydroxyl radicals. The reductases involved in these parasite’s
antioxidant systems are NADPH-dependent glutathione and
thioredoxin reductases (Mu¨ller, 2004). Although the parasites
have the enzymes isocitrate dehydrogenase and glutamate
dehydrogenase, which are also able of supplying NADPH
to the cell, the former enzyme generally oxidizes this
cofactor and the latter has been demonstrated not to be
an NADPH supplier for antioxidant systems (Preuss et al.,
2012). Furthermore, ribose 5-phosphate can be obtained
from the uptake and degradation of host purines in contrast
to being obtained from the PPP. Thus, the main role of the
PPP in Plasmodium spp. seems to be to supply NADPH.
The role of the PPP in P. falciparum is indispensable
during parasite infection. The parasite’s pathway contributes
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to 82% of total PPP activity in infected red blood cells
(IRBCs) and 72% in G6PDH-deficient IRBCs (Atamna,
Pascarmona & Ginsburg, 1994). The highest NADPH
demand appears when the parasite has reached maturation
(trophozoite stage) in IRBCs, which is consistent with
an increase in G6PDH activity in IRBCs during this
period (Atamna et al., 1994). As discussed in Section VI.1,
G6PDH-deficient hosts (46% females heterozygous; 58%
males hemizygous) have increased resistance to malaria
(Cappellini & Fiorelli, 2008). Although this resistance is
not fully understood, two hypotheses have been proposed:
one suggests that the oxidative stress in G6PDH-deficient
erythrocytes may be the cause of impaired infection; the
other proposes that these infected erythrocytes are more
easily recognized and destroyed by the host’s immune system
(Mu¨ller, 2004).
(c) The alternative PPP of Entamoeba histolytica
An alternative PPP is found in the parasite, Entamoeba
histolytica. This parasite lacks G6PDH, 6PGDH and TAL
(Barrett, 1997; Husain et al., 2012) and has developed an
alternative hexose–pentose interconversion pathway for the
formation of pentose phosphates. This alternative pathway
is constituted of several reactions catalysed by TKL, FBA
and phosphofructokinase (PPi-dependent) (Susskind, Warren
& Reeves, 1982) (Fig. 5C). When Entamoeba histolytica is
exposed to oxidative stress, metabolites of the non-oxidative
branch of the PPP, glycerol and chitin biosynthesis are
increased, a process attributable to an inhibition of glycolytic
enzymes which, in turn, promotes redirection of the carbon
flux (Husain et al., 2012). Thus, although the oxidative
branch is absent from the PPP in this parasite, it seems
that the non-oxidative pathway still responds to the
presence of oxidative stress. This observation is analogous
to budding yeast, where the non-oxidative PPP plays an
NADPH-independent role in the stress response too (Kru¨ger
et al., 2011).
(2) The PPP in bacterial infection
Similar to eukaryotes, the PPP and glycolysis (together
with overlapping reaction sequences such as the
Entner–Doudoroff pathway) constitute core carbon
metabolism in bacteria (Sprenger, 1995). As in eukary-
otes, the PPP is required to provide NADPH equivalents,
nucleotides and sugar phosphate precursors. An impor-
tant additional function however concerns the provision of
sedoheptulose 7-phosphate for the initiation of lipopolysac-
charide (LPS) biosynthesis (Taylor et al., 2008). Moreover,
the PPP appears to be the only pathway allowing bac-
teria to utilize sugars such as d-xylose, d-ribose, and
l-arabinose, which cannot be catabolised by other means
(Wood, 1985; Sprenger, 1995; Lin, 1996). Here we briefly
introduce the role of the PPP in the bacterial infection
process and the importance of this pathway for both host
and pathogen.
(a) The PPP is required in the host response to fight microbial infection
The invasion of host cells gives rise to the activation of
defence mechanisms required for survival and pathogen
expulsion. The host response is characterized by microbial
sensors activating signalling pathways and inducing effector
mechanisms (Nish & Medzhitov, 2011). Macrophages are
responsible for the host immune response by inducing
signalling modules and alterations in cell morphology
and metabolic function (Martinon, Mayor & Tschopp,
2009; Haschemi et al., 2012). The cellular reprogramming
utilizes metabolic adaptation in response to environmental
changes. Nevertheless, there is only limited knowledge
of the bioenergetic rearrangement that takes place
during macrophage activation. Recently SHPK [formerly
carbohydrate kinase- like (CARKL)] has been identified as
a modulator of macrophage regulation during LPS-induced
infection (Haschemi et al., 2012). Reduced SHPK expression
was observed in both in vivo and in vitro experiments and
associated with macrophage type 1 (M1) polarization. By
contrast, SHPK overexpression induced a pro-inflammatory
response, characterized by the presence of nuclear factor
kappa-B (NF-κB), and an increase in the production of
intracellular superoxide radicals (probably due to sustained
sedoheptulose 7-phosphate formation), which is similar to
the neutrophil-induced response (Haschemi et al., 2012)
(Fig. 5D).
Neutrophil activation characterizes the immune response
in the Gram-negative bacterium Helicobacter pylori, the agent
causing chronic gastritis and peptic ulcer disease (Nielsen
et al., 1994; Basso, Plebani & Kusters, 2010). H. pylori
was the first microorganism to be directly associated with
stomach carcinogenesis (Sipponen & Hyva¨rinen, 1993). It
was suggested that, following H. pylori infection, neutrophil
activation rapidly increases ROS production (Obst et al.,
2000). Moreover, GSH availability, normally high in the
stomach, is rapidly depleted after H. pylori infection of the
human gastric mucosa, mainly because GSH is used for
repairing oxidative DNA lesions in gastric carcinogenesis
(Shirin et al., 2001; Basso et al., 2010). By contrast, GSH
levels were increased in mouse model infections, leading
to the hypothesis that the GSH (and the oxidative PPP,
regulating GSH synthesis) could be directly involved in the
response to the oxidative stress induced by H. pylori infection
(Matthews & Butler, 2005).
(b) The PPP is a central pathway for bacterial infection and LPS
biosynthesis
The infection process requires rapid adaptation of intracel-
lular and extracellular bacteria, involving reconfiguration of
their central carbon metabolism. This is caused predomi-
nantly by their newly encountered physical conditions and
nutrient availability (Eisenreich et al., 2010; Swanepoel &
Loots, 2014). More precisely, pathogens need to modulate
their metabolism and coordinate their life cycle in order to
develop specific virulence factors (Ray et al., 2009; Eisenreich
et al., 2010).
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Due to the presence of different microenvironments
(or niches), the host environment is character-
ized by the availability of several nutrient sources
(Brown, Palmer & Whiteley, 2008). For example,
enterohaemorrhagic (EHEC) and uropathogenic (UPEC)
Escherichia coli strains (causing haemolytic colitis and urinary
tract infection, respectively), differ in their ability to cause
infection according to their localization (i.e. nutrient
availability) (Alteri & Mobley, 2012). The mammalian
urinary tract is characterized by the presence of amino
acids and small peptides, therefore mutations in the genes
coding for the PPP and glycolytic enzymes do not affect
the pathogenicity of the UPEC E. coli. On the other hand,
EHEC E. coli needs to up-regulate both glycolysis and PPP
in order to colonize the host intestine, due to the high levels
of glycogen available which can be used as an external
carbon source (Alteri & Mobley, 2012).
Last but not least, the PPP has been found to play an
essential role in the biosynthesis of lipopolysaccharides
(LPSs). LPS is part of the external layer of Gram-negative
bacteria and is involved in not only bacterial protection
but also in the activation of the host immune response
(Raetz & Whitfield, 2002). The biosynthesis of LPS has
been intensively studied in order to provide new therapeutic
agents against Gram-negative pathogens (Wang & Quinn,
2010). One of the possible targets for drug discovery is SHI,
as characterized in E. coli, Pseudomonas aeruginosa (Taylor
et al., 2008) and H. pylori (Sarkar et al., 2012). This enzyme
converts sedoheptulose 7-phosphate from the PPP into
the lipopolysaccharide precursor glycero-manno-heptose
7-phosphate (Kneidinger et al., 2001; Valvano et al., 2002;
Taylor et al., 2008), and has therefore become a central
target for the development of new antibiotics and adjuvants.
Further investigations on the LPS biosynthetic pathway
highlighted another enzyme involved in the pathogenicity
of an E. coli UPEC strain, arabinose 5-phosphate isomerase
(API), which converts the PPP sugar ribulose 5-phosphate
into the LPS precursor arabinose 5-phosphate (Mosberg
et al., 2011) (Fig. 5E), emphasizing these PPP enzymes as
attractive targets for the development of future antibiotics.
VIII. THE ROLE OF THE PPP IN CELL
PROLIFERATION AND STEM CELLS
Cell growth necessitates biosynthesis of the required interme-
diates, such as nucleotides, amino acids, and lipid precursors.
Consequently, when proliferation is induced, cells restruc-
ture their central carbon metabolism in order to adapt to the
rise in metabolic demands. This metabolic reconfiguration
includes the shuffling of the energy flux outside the mitochon-
dria to fuel glycolysis and the PPP (Levine & Puzio-Kuter,
2010; Vander Heiden et al., 2010; Gru¨ning & Ralser,
2011; Yamamoto et al., 2014). The PPP playing a crucial,
non-redundant role in the supply of building blocks such as
ribose 5-phosphate, the molecular backbone of nucleic acids,
is consequently of central importance. Indeed, a key feature
of the metabolic transformation events accompanying cellu-
lar proliferation is the enhancement of biosynthetic capacity.
Hence, diverting the energy flux towards the non-oxidative
branch of the PPP has the key advantage of enabling the
needed nucleotide biosynthesis through the production of
ribose 5-phosphate (Deberardinis et al., 2008). In addition,
this metabolic restructuring safeguards the cellular redox
balance, by modulating NADPH production in the PPP.
Human pluripotent stem cells (PSCs), including embry-
onic stem cells (ESCs) (Thomson et al., 1998) and induced
pluripotent stem cells (iPSCs) (Takahashi et al., 2007), are
of particular interest in biomedicine given their ability to
proliferate indefinitely (self-renewal) and to differentiate
into virtually any cell type of the body (pluripotency). The
central importance of metabolism in reprogramming and
self-renewal has recently caught the attention of the stem
cell community, with most discoveries dating back to recent
years only (reviewed in (Folmes et al., 2012; Zhang et al.,
2012; Xu et al., 2013; Bukowiecki, Adjaye & Prigione, 2014)
and has revealed that the induction and maintenance of
PSCs is associated with a profound change of anabolic
demands. PSCs exhibit an elevated rate of proliferation and
distinct cell cycle features compared to common somatic cells
(Ruiz et al., 2011). Moreover, PSCs are particularly sensitive
to redox imbalance (Saretzki et al., 2008) and display low
levels of oxidatively modified proteins, lipids, and DNA
(Prigione et al., 2010). Indeed, increased ROS levels have
been shown to promote differentiation (Yanes et al., 2010).
The establishment of the proliferative PSC state has been
found to be coupled with elevated lactate generation and
enhanced glycolytic flux (Prigione et al., 2010; Folmes et al.,
2011). Moreover, upon glycolysis-activating conditions, such
as under hypoxia stimulation or after treatment with small-
molecule inducers of the master metabolic regulator
hypoxia-inducible transcription factor 1 (HIF-1) (see section
VIII-4-d), the efficiency of somatic cell reprogramming is
significantly improved (Yoshida et al., 2009; Zhu et al., 2010).
Conversely, genetic ablation of HIF-1 hampers the formation
of iPSCs (Prigione et al., 2013; Mathieu et al., 2014). Finally,
increased expression of the pyruvate kinase isozyme M2
(PKM2), which regulates the flux distribution between glycol-
ysis and the PPP (section VIII-3), has been identified in both
ESCs and iPSCs compared to somatic cells (Prigione et al.,
2013).
Currently, evidence from altered PPP metabolism in
stem cell populations mainly originates from the analysis
of their gene expression profiles. Genes regulating the first
steps of glycolysis were up-regulated in PSCs compared
to somatic cells, including glucose uptake (SLC2A3) and
glucose phosphorylation to glucose 6-phosphate (HK3 and
GCK ) (Prigione et al., 2011; Varum et al., 2011). Enzymes
of the final steps of glycolysis (such as PGAM2, ENO,
PKLR, and LDH ) are up-regulated in PSCs. On the
other hand, the expression level of the glycolytic enzymes
downstream of glucose 6-phosphate, including GPI, PFK,
and ALDO, is reduced in PSCs, while the level of genes
involved in the non-oxidative branch of the PPP (RPIA
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and TKT ) is augmented (Folmes et al., 2011; Prigione
et al., 2011; Varum et al., 2011). Hence, the transcriptional
data of PSCs suggest that glycolytic intermediates may
be diverted into the PPP, in order to support both the
biomass accumulation and redox homeostasis that are
associated with the maintenance and derivation of PSCs.
Accordingly, LC-MS/MS-based metabolite quantification
detected the accumulation of glucose 6-phosphate and
decreased dihydroxyacetone phosphate in PSCs compared
to fibroblasts (Prigione et al., 2011), which may be indicative
of overall increased metabolic activity due to proliferation
and possibly specific PPP activation. Elevated protein
expression of hexokinase II (HXK2), which causes a higher
glycolytic rate than isoform I, has also been observed
in the mitochondria of PSCs (Varum et al., 2011). This
is of particular interest since HXK2 activity may be
stimulated under hypoxia by the p53-inducible target
TP53-induced glycolysis and apoptosis regulator (TIGAR)
(see sectionVIII-4-a) to induce the PPP and preserve redox
homeostasis (Cheung, Ludwig & Vousden, 2012).
Finally, the importance of the PPP for the maintenance
of the pluripotent state is supported by the findings that
G6PDH-depleted ESCs proliferate at a reduced rate and,
upon oxidant exposure, are incapable of increasing the
PPP flux, thus resulting in apoptotic cell death (Filosa
et al., 2003; Fico et al., 2004). Furthermore, genetic or
small-molecule-based inhibition of the PPP forces PSCs
to exit the self-renewal state and start the differentiation
process (Manganelli et al., 2012). Overall, it appears that
promoting the activation of the PPP is functionally critical
to support the establishment and the maintenance of the
proliferative conditions associated with the undifferentiated
PSC state. It is however not clear to which extent the
metabolic reconfiguration has an active role in maintaining
pluripotency, or whether changes in energy metabolism are
causative in driving differentiation. Evidence for an active
role of the PPP in supporting cell proliferation has however
been found by studying the metabolism of cancer cells.
(1) The role of the PPP in deregulated cell
proliferation and the pathogenesis of cancer: the
Warburg effect
Rising attention has recently been paid to deregulated
cell proliferation when it has been noticed that malignant
transformation and metabolic reprogramming may be
intimately intertwined. Despite a vast amount of research,
cancer still represents the second most common cause of
death in the world, beaten to the top only by cardiovascular
diseases. While the last decade has substantially changed
the way cancer therapy is performed, the majority of
newly approved molecular-targeted drugs (e.g. antibodies
against growth factors or their receptors, tyrosine kinase
inhibitors and other small molecules) failed to result in
significant and long-lasting improvement of therapy efficacy
(Fojo & Parkinson, 2010). This is partially explained by
the hallmark genomic instability of malignant cells that
results in an impressive propensity to adapt to and,
ultimately, resist inactivation of ‘cancer-specific’ signalling
pathways (Bock & Lengauer, 2008; Gillies, Verduzco &
Gatenby, 2012). Inhibition of processes that are absolutely
essential and non-redundant for tumour cell proliferation
is a promising strategy to improve cancer therapy.
Tumour-specific metabolism clearly represents such a
process. Despite being recognized nearly a century ago,
the fundamental importance of metabolic deregulation
for cancer pathogenesis has escaped the appreciation of
most cancer researchers for decades. It was not until
the post-genome era that metabolic reprogramming was
widely accepted as an emerging hallmark of cancer
(Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011).
Recently however, characterization of cancer metabolism
has become the focus of a rapidly growing research
community, taking advantage of the improved analytical
and increasingly also computational methodology to
identify fascinating and unexpected interactions (Weinberg,
2014). Observed changes in metabolism are in no way
‘trivial’, indeed can be quite specific dependent on both
the responsible genetic lesion and tumour tissue type
(Yuneva et al., 2012). While the majority of published
work analysed the role of glycolysis, glutaminolysis and
mitochondrial activity, the importance of the PPP for
malignant transformation remained elusive for quite some
time.
Otto Warburg was not only able to identify some of the
first enzymes and co-enzymes of central metabolism, but
at the same time, was one of the first research pioneers
that recognized the importance of altered metabolism
for tumour growth. He and his co-workers discovered
an increase in glucose uptake and lactate production
in concert with a decrease in oxygen uptake (known
as the ‘Warburg effect’), reviewed in (Warburg, 1956).
Intriguingly, the elevation in glycolytic flux also occurred
under sufficient oxygen supply (aerobic glycolysis). Based
on these results, Warburg concluded that cancer cells must
suffer from defects in their respiratory machinery. Today,
we know that although many cancers show reduced activity
of oxidative phosphorylation (OXPHOS; (Ferreira, 2010;
Cairns et al., 2011)), most cancers [with important exceptions,
oncocytoma for instance (Mayr et al., 2008)], possess a fully
functional respiratory chain and are therefore biochemically
fully capable of using the respiratory chain for ATP
production.
But why are cancer cells then not fully exploiting
this efficient ATP-producing machinery? A cutback in
OXPHOS seems counterintuitive since rapid proliferation
demands large amounts of energy. This observation implies
that other factors than ATP production are more limiting for
the cancer cell. Recent observations indicate that a balanced
redox state, achieved in part by increased PPP activity, is
essential for tumourigenesis (Anastasiou et al., 2011; Gru¨ning
& Ralser, 2011; Tosato et al., 2012). A more disputed theory
concerns the cross-feeding of cancer cells through lactate,
termed the ‘Reverse Warburg effect’ (Pavlides et al., 2009).
Although this theory has attractive components, it fails to
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explain some aspects of the effect; for instance it does not
explain why other organisms, like yeast cells, also show
Warburg-like metabolic reconfigurations despite not sharing
lactate. Importantly, however, all these studies indicate
that the often heard hand-waving explanation ‘Respiration
is reduced in cancer cells to save carbon equivalents for
biosynthesis’ is to be questioned as a cause for the Warburg
effect: First, respiratory activity does not compete with aer-
obic glycolysis for carbons, as aerobic glycolysis is followed
by lactate excretion instead of pyruvate decarboxylation.
Second, also the PPP contains a CO2-producing reaction.
Thus, Warburg like cells have a negative carbon balance.
Oxidative stress is a major cause of damage for macro-
molecules and can eventually lead to cell death. On the
other hand, a certain amount of oxidizing equivalents
are certainly necessary for cell physiology, and thus, only
situations with constantly or periodically elevated ROS
levels can be considered as a risk factor for tumourigenesis.
ROS-induced DNA damage can lead to cancerogenic
mutations and genomic instability, and ROS also trigger
inflammatory pathways and have a stabilizing effect on
HIF-1; a transcription factor highly expressed in cancer
cells (Gao et al., 2007; Perera & Bardeesy, 2011; Wu & Le,
2013). Therefore, the pool of intracellular ROS must be
kept balanced and below a toxic threshold – a drastic shift
towards oxidation would cause tumour cell death (Gao et al.,
2007; Perera & Bardeesy, 2011). Thus, dynamic tuning of
the metabolic network as well as the antioxidant systems,
involving glycolytic metabolite accumulation and PPP acti-
vation, is of fundamental importance to keep the production
of cellular building blocks, energy and reducing equivalents
in check. Vice versa however, pro-oxidant therapies could
prove helpful in inhibiting tumour cell proliferation.
(2) Evidence for enhanced PPP activity in cancer
cells
Gene and protein expression analyses together with immuno-
histochemistry are widely applied as surrogate methods to
assess the role of specific factors for cancer pathogenesis.
However, while these methods are certainly useful and have
helped to identify numerous molecules important for cancer
biology, a valid and detailed characterization of metabolic
pathways cannot be achieved by them. Metabolic pathways
appear mostly regulated by post-translational mecha-
nisms (Daran-Lapujade et al., 2004; Buescher et al., 2012;
Kochanowski, Sauer & Chubukov, 2013). In addition, flux
of the PPP is dependent on the level of co-factors (NADP+
for the oxidative PPP), substrate availability (non-oxidative
PPP), and the flux through glycolytic enzymes. Hence,
information about the abundance of mRNA and also
protein levels is limited to pinpoint accurately changes
in PPP activity and their potential causal importance for
cancer biology, so it is required to determine these values in
concert with flux and/or metabolite concentrations. Due to
the difficulty in applying these techniques in heterogeneous
tumours, it is hence not surprising that published literature
is rather scant. Fortunately, G6PDH is an informative
exception as its enzyme activity in tumours is well studied
and was increased in various human cancer types when
compared to the respective benign control tissue, e.g.
cervix, uteri, prostate and breast (Pedersen, 1975; Zampella,
Bradley & Pretlow, 1982; Bezwoda et al., 1985). To the
best of our knowledge, there is less information available
about tumour-specific activities of the non-oxidative PPP,
especially for its key enzymes TAL and TKL.
Assessment of enzyme activity however points towards
modified PPP flux in cancer. Stable isotope resolved
metabolomics (SIRM), indicates enhanced PPP activity in
the human breast cancer cell line MCF7 when compared
to non-transformed mammary epithelial cells (Meadows
et al., 2008). Similar results have been obtained in renal
cell carcinoma where altered activity of the PPP has been
identified as a key metabolic feature of the cancer state
(Catchpole et al., 2011). In addition, PPP adaptation could
be crucial for cancer cells that use glucose alternatives, such
as fructose, for their carbohydrate needs. There is evidence
that in pancreatic cancer cells, fructose is preferentially
metabolized via the non-oxidative PPP supporting tumour
growth (Liu et al., 2010). In this context, a homologue of
TKL, TKL-like protein (TKTL1) is detected in tumour
tissue and its expression level has been correlated with the
progression of cancer (Diaz-Moralli et al., 2011; Kayser et al.,
2011). However, due to the difficulty in detecting TKTL1
enzymatic activity it is currently undecided whether TKTL1
participates in the PPP or not (Meshalkina et al., 2013).
As an alternative to the classical biochemical approaches,
functional imaging is becoming increasingly sophisti-
cated and has shown promise as another more direct
method to assess metabolic changes in vivo. A recent
study used intravenous infusion of [1,2-13C2] glu-
cose, followed by 13C NMR analysis of the micro-
dissected tumour mass and non tumour-bearing surround-
ing brain, to assess PPP flux relative to glycolytic flux.
The malignant tissue in this study did not show enhanced
PPP flux relative to glycolysis, when compared with the
surrounding benign brain tissue (Marin-Valencia et al.,
2012a; Marin-Valencia et al., 2012b), and it was suggested
that damage to the surrounding brain was confounding the
measurements. While the latter two studies demonstrate the
potential of measurements for the PPP flux, it is clear that
additional data are needed from a broad spectrum of tumours
for a more comprehensive picture of PPP activity in cancer.
New opportunities arise from the use of hyperpolarized
NMR tracers, as these allow non-invasive and real-time
assessment of metabolic flux in vivo. The technique has
recently been translated to the clinic with a study in prostate
cancer (Nelson et al., 2013). Intriguingly, in studies on E.
coli, yeast and cancer cells, in vitro signals from glycolytic
intermediates have been detected, such as dihydroxyacetone
phosphate, and also a signal that has been assigned to
6-phosphogluconate, offering the potential for in vivo
measurements of PPP flux as well. Such measurements have
recently been reported for tumors in vivo, where hyperpo-
larized [U-2H, U-13C] glucose and the lactate formed from
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
The pentose phosphate pathway 949
it were imaged and the resonance previously assigned to
6-phosphogluconate was observed (Rodrigues et al., 2014).
(3) Enzymatic switches enable metabolic
adaptation of cancer cells
Different enzymatic switches could be involved in trig-
gering and modulating metabolic reprogramming towards
increased PPP flux. Proliferating mammalian cells have
increased levels of glycolytic enzymes, one of these is
represented by PK isozymes M1/M2 (PKM1/2) (Bock
& Lengauer, 2008; Christofk et al., 2008; Hitosugi et al.,
2009; Bluemlein et al., 2011). PK catalyses the ‘final’ step in
glycolysis and converts PEP into pyruvate; a reaction which
yields ATP, and is thus required for the net gain in glycolytic
energy production (Fraenkel, 1986).
Most human tissues are dominated by the expression of
one of two mutually exclusive spliceforms of the PKM gene:
PKM1 and PKM2 (Mazurek et al., 2005; Bluemlein et al.,
2011). In most human tissues whether healthy or cancerous,
(bladder, liver, colon, lung, kidney, thyroid, fibroblasts,
epithelial cells), but not in muscle and potentially neurons,
PKM2 is the dominantly expressed isoform over PKM1
(Bluemlein et al., 2011). At least liver and red blood cells
express an additional PK isoform, known as PKLR (Zanella
& Bianchi, 2000).
Among PKM-expressing tissues, the total PKM expres-
sion level and the distribution between the two isoforms
varies significantly, and ranges from 55% PKM2 over
PKM1 of total PKM in (muscle-rich) bladder tissue,
to up to 96% PKM2 of total PKM in colon tissue.
At the same time, in absolute values, the PKM content
ranged from ∼10 fmol/μg total protein in thyroid to
300 fmol/μg total protein in colorectal carcinoma (Bluem-
lein et al., 2011). Hence, the expression level of the PKM gene
appears to be an important determinant of total pyruvate
kinase activity and is highly dependent on the tissue. In many
cancer cells PKM2 expression is increased when compared
to tissue-matched controls (Ashrafian et al., 2010; Bluemlein
et al., 2011; Zhou et al., 2012). Despite the total protein
amount being up-regulated, overall PK activity however
does not increase accordingly, or it is inhibited, suggesting
that the specific PKM activity is lowered in the tumour
cells (Hitosugi et al., 2009; Vander Heiden et al., 2010). This
modulation of PK activity creates the opportunity to switch
between high glycolytic flux, or induce a metabolic reconfig-
uration towards OXPHOS and an activated PPP. In contrast
to PKM1 that is a tetramer with high constitutive activity
(Imamura & Tanaka, 1972; Wu & Le, 2013), PKM2 can be
flexibly tuned and allosterically modulated in activity and
switches between monomeric, dimeric and tetrameric states
(Morgan et al., 2013). Allosteric activation of PKM2 can
be achieved by interaction with fructose 1,6-bisphosphate,
succinylaminoimidazolecarboxamide ribose 5′-phosphate
(SAICAR) and serine (Chaneton et al., 2012; Keller, Tan &
Lee, 2012). In addition, post-translational modifications can
modulate PKM2 activity. For example, phosphorylation
at tyrosine 105 prevents the formation of the more active
tetrameric form of PKM2 (Hitosugi et al., 2009), and
P300/CBP-associated factor (PCAF)-mediated acetylation
on lysine 305 reduces activity (Wang et al., 2010). During
high ROS levels, lower PK activity could be essential to
maintain cell survival. Similarly to respiring yeast (section
III), cancer cells accumulate PEP because of reduced
PK activity (Anastasiou et al., 2011; Gru¨ning et al., 2011).
Oxidation of PKM2 at cysteine 358 can decrease its activity
and redirect glycolytic intermediates towards the PPP for
the production of NADPH. Disruption of this mechanism
can exacerbate oxidative stress and subsequently decrease
proliferation in cancer cells (Anastasiou et al., 2011).
What does link decreased PK activity and increased
cellular oxidative capacity? The mechanism seems to depend
on the glycolytic block and PEP accumulation. PEP interferes
with other glycolytic reactions, such as phosphoglycerate
mutase, glucokinase, GPI, PFK, FBA and TPI (Ogawa
et al., 2007; Fenton & Reinhart, 2009; Gru¨ning et al., 2011;
Gru¨ning et al., 2014). The latter can directly lead to increased
PPP activity and stress protection. Despite in vitro kinetics
indicating a low flux control coefficient of TPI (Knowles
& John, 1977), in vivo experiments detect increased PPP
activity when TPI activity is only slightly compromised
(Ralser et al., 2007). TPI inhibition is sufficient to cause a
block in upper glycolysis and an increase in PPP metabolites
(Gru¨ning et al., 2011; Gru¨ning et al., 2014). This redirection of
metabolites by the PK-PEP-TPI feedback loop enables cells
to adapt to a higher level of ROS and protect from oxidative
damage (Ralser et al., 2007; Gru¨ning et al., 2014). TPI
thus might represent a key enzymatic switch for metabolic
reprogramming. Although low PK and TPI activity limit the
ATP yield from energy metabolism, the cell’s redox balance
is maintained which could be more important for cancer
survival (Cairns et al., 2011; Gru¨ning & Ralser, 2011).
(4) Interaction of the PPP with oncogenic pathways
(a) p53
The transcription factor p53 represents a tumour suppressor
with well-established functions on genomic integrity,
apoptosis and cell cycle control (Vazquez et al., 2008). p53
is the most commonly mutated gene in human cancers and
its loss constitutes a pivotal mechanism of therapy failure
(Bensaad et al., 2006; Rohwer et al., 2010). It became evident
in recent years that p53, in addition to the functions outlined
above, exerts control over metabolic pathways. The p53
target gene TIGAR was shown to dampen glycolysis by
lowering the level of fructose 2,6-bisphosphate which is
a powerful allosteric activator of PFK1. As a result the
glycolytic intermediates can be diverted to the oxidative
or non-oxidative branch of the PPP (Fig. 6). This leads
to decreased cellular levels of ROS due to the action of
NADPH, ultimately resulting in enhanced cell survival and
growth (Bensaad et al., 2006). In highly proliferative tissues
such as the intestine, a lack of TIGAR in vivo leads to
decreased regeneration after acute stresses such as ulcerative
colitis and irradiation, indicating an important role of
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TIGAR in proliferation (Cheung et al., 2013). Consistently,
overexpression of TIGAR has been observed in a number
of tumour types, and also in invasive cancer cells compared
to normal tissues (Wanka, Steinbach & Rieger, 2012; Won
et al., 2012; Cheung et al., 2013). In an in vivo model of
intestinal adenoma where adenomatous polyposis coli (APC)
is deleted in LGR5+ intestinal stem cells, TIGAR deficiency
decreases tumour burden and average tumour size, which
results in increased disease-free survival in these mice.
Tumour intestinal crypts isolated from these mice showed
that the in vitro growth of the TIGAR-deficient tissues can be
rescued by the addition of antioxidants and nucleosides, again
indicating an important role of TIGAR in increasing PPP
during proliferation. While the role of TIGAR in promoting
tumour growth seems to be counterintuitive to p53 as a
tumour suppressor, TIGAR expression is uncoupled from
p53 expression in various cell lines (Cheung et al., 2013).
Hence, it is possible that a p53 target protein such as TIGAR
can become oncogenic when it is not properly regulated by
p53. Recently, it has been shown that TIGAR predominantly
functions as phosphoglycolate-independent 2,3-bisphos
phoglycerate phosphatase (Gerin et al., 2014). Another
interpretation is thus that p53 could stimulate the
non-oxidative PPP via TIGAR by directly targeting lower
glycolysis. In contrast to this activity of a p53-target gene,
p53 itself can inhibit G6PDH and regulate its activity; this
results in reduced PPP activity and a redirection of the central
carbon flux towards increased glycolytic activity (Jiang et al.,
2011). As a result, p53-deficient cells display enhanced lipid
synthesis as well as reduced sensitivity towards oxidative
stress-induced cell death as a functional consequence of
higher oxidative PPP activity (Jiang et al., 2011). Taken
together, p53 seems to influence the PPP antithetically, both
as an inhibitor (via direct influence on G6PDH) and as an
activator (via TIGAR). These opposing functions of p53
may reflect the different roles of p53 depending on the
severity of the damage to the cell. During transient and
mild stress, p53 may act as a pro-survival mediator for
repair and regeneration. However, if the damage is too high
and persistent, p53 may switch off the pro-survival mode
for the proper elimination of irreversibly damaged cells. In
some cases, as a result of p53 activity, the homeostasis and
integrity of the tissue as a whole is preserved. Interestingly,
p73 (a p53 relative) was shown to enhance the PPP by
activating the expression of G6PDH under conditions where
p73 showed tumour-promoting activities (Du et al., 2013).
While illustrating the complexity of function of the p53
family of proteins, these studies support the general notion
that flux through the PPP supports cancer cell growth.
(b) ATM kinase
PPP activity can be also stimulated by the kinase
ataxia telangiectasia mutated (ATM). ATM is a serine/
threonine kinase which is activated by DNA double-
strand breaks and phosphorylates enzymes which are
required for DNA checkpoint control and cell cycle arrest
(Furgason & Bahassi, 2013). It phosphorylates the heat
shock protein 27 (HSP27) which forms a complex with the
first enzyme of the oxidative branch of the PPP: G6PDH.
This interaction activates G6PDH and increases its activity
supporting elevated PPP flux (Cosentino et al., 2011) (Fig. 6).
Therefore, by connecting genome stability and cell cycle
control to PPP activation and metabolic adaptation, ATM
represents another crucial hub for cellular homoeostasis
during tumourigenesis (Cosentino et al., 2011; Kru¨ger &
Ralser, 2011; Ditch & Paull, 2012).
(c) K-ras
The proto-oncogene K-ras is found activated in a number of
human cancers, in particular adenocarcinomas of the pan-
creas, lung and colon (Downward, 2003). The observation
that K-ras-transfected murine fibroblasts display enhanced
resistance against oxidative stress via NADPH-mediated
glutathione recycling first pointed towards a potential
importance of the PPP for K-ras-induced transformation
(Recktenwald et al., 2008). Subsequently, it was found that
oxidative stress is induced upon matrix detachment of cells
and that resistance against detachment-induced cell death
(anoikis) largely depends on antioxidant capacity (Schafer
et al., 2009). Intriguingly, anoikis resistance, which represents
a central hallmark of malignant cells and a fundamental
prerequisite for metastatic dissemination, in K-ras-driven
human colon and mammary cancer cells, depends on
functional integrity of the PPP (Weinberg et al., 2010).
While these results point towards a functional importance
of PPP-mediated antioxidant capacity for K-ras-driven
tumourigenesis, ROS generation has shown to be essential
for the full oncogenic potential of K-ras (Weinberg et al.,
2010). These apparently contradictory results clearly need
further experimental clarification before a clear-cut picture
of the interplay between K-ras and the PPP during malignant
transformation can be proposed (Fig. 6).
(d ) HIF-1
The hypoxia-inducible transcription factor HIF-1 is found
overexpressed in the majority of human cancers and regulates
pivotal pro-tumourigenic features such as angiogenesis,
glucose uptake and glycolysis as well as resistance towards
apoptosis and anoikis (Rohwer et al., 2013). Research
on the role of HIF-1 for glucose metabolism was long
dominated by HIF-1’s robust effect on glucose transport
and glycolysis while experimental data supporting a role for
HIF-1 in the control of cancer-associated PPP activity is
intriguingly meagre. Analyses of the importance of oxidative
stress during the pathogenesis of Alzheimer’s disease first
reported a functional role of HIF-1 for enhanced PPP
activity (Soucek et al., 2003) (Fig. 6). Later, experimental
evidence supported a critical role of HIF-1-mediated PPP
activation in cellular antioxidant capacity of neuroblastoma
cells (Guo et al., 2009). The most compelling experimental
evidence in this regard was published by Craig Thompson’s
group: analysing chronic myeloid leukemia (CML) cells,
they reported robust activation of HIF-1 in cells exhibiting
Biological Reviews 90 (2015) 927–963 © 2014 The Authors. Biological Reviews published by John Wiley & Sons Ltd on behalf of Cambridge Philosophical Society.
The pentose phosphate pathway 951
Fig. 6. The pentose phosphate pathway (PPP) is associated with several cancer- and cell-proliferation-related signalling cascades.
The p53 pathway can stimulate the PPP by inhibiting phosphofructokinase 1 (PFK1) through TP53-induced glycolysis and apoptosis
regulator (TIGAR), and by inhibiting glucose 6-phosphate dehydrogenase (G6PDH). This enzyme is also targeted by the ataxia
telangiectasia mutated (ATM) kinase, which increases G6PDH activity by phosphorylating heat shock protein 27 (HSP27), and
an NAD-dependent deacetylase (SirT2), which acts on this enzyme directly by de-acetylation. All three mechanisms activate the
oxidative branch of the PPP, which is also controlled by the mammalian target of rapamycin complex 1 (mTOR) pathway. Cancer
signalling mechanisms operate alongside allosteric and metabolic regulation. For instance, reduced pyruvate kinase PKM2 activity
leading to triosephosphate isomerase (TPI) inhibition increases the carbohydrate flux towards the PPP, achieving a metabolic
self-regulation that counteracts oxidative stress. The activity of the PPP itself has an influence on cancer signalling pathways. The
antioxidant capacity of the PPP modulates proto-oncogene k-ras-driven tumourigenesis; concurrently, reactive oxygen species (ROS)
can potentiate the oncogenic activity of k-ras (the two opposing regulations are highlighted). The PPP has also been associated
with drug resistance and hypoxia. Depending on the sensitivity to imatinib, chronic myeloid leukaemia (CML) cells can either
exhibit reduced (sensitive cells) or increased (resistant cells) transketolase (TKL) activity after hypoxia-inducible transcription factor
1 (HIF-1) activation. F 2,6-BP, fructose 2,6-biphosphatase; P13K (Phosphatidylinositol-3-kinase), Akt (protein kinase B); PEP,
phosphoenolpyruvate.
resistance towards the tyrosine-kinase-inhibiting therapeutic
imatinib (Zhao et al., 2010). This HIF-1 activation was
associated with reduced flux through the oxidative branch
of the PPP while the glycolytic rate was significantly
enhanced. On the other hand, the non-oxidative PPP
branch was found activated in a TKL-dependent manner
in cells with stabilized HIF-1, thereby supplying ribose
synthesis essential for cellular proliferation (Zhao et al., 2010).
Chemical inhibition of TKL resulted in enhanced imatinib
sensitivity in vitro and in vivo against CML, pointing towards
a functional role of HIF-1-driven non-oxidative PPP in
mediating resistance against targeted therapies. These results
are especially intriguing as imatinib represents the only
targeted therapeutic that was able to result in undisputed
and long-lasting clinical benefit of patients with cancer. This
work supports the notion of HIF-1 as a pivotal mediator of
therapy failure and points towards HIF-1-dependent control
of cellular metabolism as an important molecular mechanism
(Rohwer & Cramer, 2011).
(e) PI3K-Akt/mTORC1
Aberrant activation of the signalling cascade compris-
ing phosphatidyl inositol kinase (PI3K), protein kinase B
(PKB/Akt) and the mammalian target of rapamycin com-
plex 1 (mTORC1) is commonly observed in the majority of
human cancers (Laplante & Sabatini, 2012). It became evi-
dent in recent years that mTORC1 exerts pro-tumourigenic
activity not only via its well-established roles in protein
synthesis and autophagy, but also via elaborate control
over cellular metabolism. A genomic approach unravelled
that mTORC1 induces a variety of genes that encode
for specific metabolic pathways, e.g. glycolysis, lipid and
sterol biosynthesis as well as both branches of the PPP (Du¨vel
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et al., 2010). Despite these encouraging results, the functional
importance of the PPP for mTORC1-driven cancers as well
as the molecular nature of mTORC1 activation of PPP genes
remains elusive. The antioxidant capacity needed to promote
survival of tumour cells after detachment from the extracel-
lular matrix depends on PI3K-Akt-induced activation of the
oxidative PPP (Schafer et al., 2009) (Fig. 6).
(f ) Alternative pathways of PPP activation in cancer
The notion that increased PPP activity is beneficial for
cancer cells is also supported by other studies that propose
alternative mechanisms of PPP activation in cancer cells.
For example, phosphofructokinase 1 (PFK1) is inhibited
in cancer cells through glycosylation, drives PPP flux
and supports cancer cell growth (Yi et al., 2012). Vice
versa, the depletion of 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatase 4 (PFKFB4) inhibits cancer cell growth
by lowering flux through the PPP (Ros et al., 2012).
Moreover, a study addressing the plant stilbenoid resveratrol
indicates that its suppressive function on human colon
cancer cell proliferation is attributable to PPP targeting and
talin-focal adhesion kinase (talin-FAK) signalling pathways
as well (Vanamala et al., 2011).
(5) Conclusions about the role of the PPP in cancer
metabolism
While the prognosis of certain types of cancers (e.g. breast
and colon cancer) has improved in recent years, we are
still eagerly awaiting successful clinical translation of the
billions of funding and an uncountable number of working
hours that have been invested in cancer research in the
last 40+ years. Otis W. Brawley, chief medical officer of
the American Cancer Society, once said ‘One cancer cell
is smarter than 100 brilliant cancer scientists’. We still
need to unravel the basic principles that enable malignant
transformation, unchecked proliferation, systemic spread
and therapy resistance. There is good reason to believe
that understanding cancer metabolism might provide an
important contribution to these attempts. The study of the
PPP could be central, as the pathway is at the crossroads of
both oncogenic signalling and biosynthetic pathways. In this
respect, first results are promising: in a recent study, PPP
activity was predictive for the efficacy of cancer therapeutics
(Folger et al., 2011).
IX. THE ROLE OF THE PPP IN BRAIN ENERGY
METABOLISM
The brain energy demands to maintain its physiological sig-
nalling activities are extremely high. Although it represents
only 2% of the total body mass, the adult human brain is
believed to consume about 20% of oxygen respired at rest
(Silver & Erecin´ska, 1998; Be´langer, Allaman & Magistretti,
2011). A developing brain might have even greater require-
ments, as estimates suggest that an infant’s brain can utilize
more than 40% of basal metabolic rate (Goyal et al., 2014).
These large amounts of energy are needed for the main-
tenance and restoration of ionic gradients and for synaptic
transmission (Attwell & Laughlin, 2001). The majority of
ATP is generated through OXPHOS, therefore implying
the strict reliance of neuronal activity on mitochondria func-
tionality and oxygen supply (Ames, 2000; Erecinska, Cherian
& Silver, 2004). Accordingly, mitochondrial impairment has
a great impact on neuronal function and survival (Nicholls
& Budd, 2000; Kann & Kova´cs, 2007), and it is considered a
key pathogenic player in several neurodegenerative and neu-
rodevelopmental disorders (Fiskum, Murphy & Beal, 1999;
Beal, 2005).
Glucose represents the normal obligatory energy substrate
of the brain, and 25% of its daily intake is assumed to be
dedicated to cerebral functions (Cremer, 1982; Be´langer
et al., 2011). A steady glucose supply is necessary since the
central nervous system (CNS) is able to store only a limited
amount of glycogen within astrocytes (Brown & Ransom,
2007), glial cells outnumbering neurons in the human brain.
Interestingly, quantitative measurements of whole-brain
metabolism showed that about 10% of consumed glucose is
in excess of oxygen utilization (Fox et al., 1988). Therefore,
glycolysis-based metabolism appears of fundamental impor-
tance for the energetic needs of active neuronal tissue. Studies
of primary cultures of glia and neurons helped to demon-
strate the physiological metabolic compartmentalization
of the CNS. In particular, astrocytes are mainly glycolytic
and convert glucose into lactate (Itoh et al., 2003). This
lactate can then be transferred to neurons via the so-called
‘astrocyte–neuron lactate shuttle’ and eventually employed
by the neurons for OXPHOS-based ATP generation (Pel-
lerin & Magistretti, 1994; Kasischke et al., 2004). This model
is supported by a cell-type-specific expression pattern of reg-
ulatory members of carbon metabolism (Lovatt et al., 2007).
These include glucose transporters (GLUT1 in astrocytes
and GLUT3 in neurons), lactate dehydrogenase (LDH1 in
astrocytes favouring lactate generation and LDH5 in neu-
rons supporting pyruvate formation from lactate), and lactate
transporter (monocarboxylate transporter MCT1/4 in astro-
cytes promoting lactate release and MCT2 in neurons pro-
moting lactate uptake) (Fig. 7) (Bittar et al., 1996; Ames, 2000;
Be´langer et al., 2011).
An interesting consequence of the metabolic coupling
between astrocytes and neurons is the peculiar neuronal
dependence on PPP activity. Indeed, lactate utilization as an
oxidative substrate for energy production in neurons may
represent a mechanism for circumventing glycolysis and thus
sparing neuronal glucose for the PPP (Bolan˜os, Almeida &
Moncada, 2010). In particular, a fundamental regulatory
role has been proposed for the enzyme 6-phosphofructose-2-
kinase/fructose-2,6-biphosphatase-3 (PFKFB3), which gen-
erates fructose 2,6-bisphosphate (F2,6BP), a potent activator
of the rate-limiting glycolytic enzyme phosphofructokinase-1
(PFK1) (Hue & Rider, 1987). Due to constant proteasomal
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Fig. 7. The pentose phosphate pathway (PPP) in neuronal energy metabolism. Schematic representation of glucose metabolism in
neurons (left) and astrocytes (right). Metabolic regulators differentially expressed between neurons and astrocytes are highlighted.
Summarized is evidence that astrocytes ferment glucose to lactate which is secreted aside GSH into the intracellular space. Neurons
then uptake lactate and GSH; lactate is then converted to pyruvate and enters the tricarboxylic acid cycle to generate ATP over the
respiratory chain. Abbreviations: as in Table 1; GSH, glutathione; GSSG, glutathione disulfide; GLUT, glucose transporters; GR,
glutathione reductase; GPx, glutathione peroxidase; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter.
degradation, PFKFB3 is absent in neurons and cannot
be activated upon inhibition of mitochondrial respiration
(Almeida et al., 2001; Herrero-Mendez et al., 2009). On the
contrary, PFKFB3 is expressed in astrocytes was upregulated
upon mitochondrial impairment in order to increase the gly-
colytic rate (Herrero-Mendez et al., 2009). Therefore, the
high neuronal sensitivity to mitochondrial dysfunction may
be due to their inability to sustain elevated glycolysis because
of their dependence on PPP-based utilization of glucose. A
similar mechanism may also be present in cancer cells, where
PFKFB3 has been reported to display reduced methylation
and enhanced degradation in the proteasome, resulting in
the shunt of glucose away from glycolysis and towards the
PPP (Yamamoto et al., 2014).
The main reason underlying neuronal dependence on
glucose metabolism via the PPP may be the maintenance
of redox homeostasis (Fernandez-Fernandez, Almeida &
Bolan˜os, 2012). Indeed, to counteract the increase in ROS,
common by-products of OXPHOS, neuronal cells would
need an antioxidant defence mechanism constantly in place.
To this end, the production of NADPH within the oxidative
branch of the PPP is critical, as it represents the main
electron donor for the generation of reduced glutathione
(GSH) through the enzyme glutathione reductase (GR).
GSH is in turn employed as electron donor for the reduction
of detrimental peroxides (ROOH) by glutathione peroxidase
(GPx) (Dringen, 2000). Interestingly, although this process
may be essential in neurons, it has been shown that
astrocytes are better equipped to stimulate the PPP, and the
consequent NADPH generation, in response to oxidative
stress (Ben-Yoseph, Boxer & Ross, 1996a; García-Nogales,
Almeida & Bolan˜os, 2003). Neurons are also less capable
than astrocytes in utilizing extracellular cysteine, used as
precursor of GSH, and thus rely on the uptake of GSH
that has been produced and released by the astrocytes
(Dringen, 2000). These data emphasize the susceptibility of
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neuronal cells to redox imbalance and their crucial necessity
for PPP-based glucose metabolism (Ben-Yoseph, Boxer &
Ross, 1996b). In accordance, brain PPP activity has been
found induced upon experimental brain injury in mice and
after traumatic brain injury in humans (Bartnik et al., 2005;
Dusick et al., 2007). Furthermore, malfunction of the PPP
is associated with the appearance of neurological symptoms
(Herken, Lange & Kolbe, 1969).
Recent findings suggest a second reason behind the
importance of the PPP in brain metabolism. A meta-
analysis of glucose and oxygen consumption throughout the
human lifespan and among different brain regions suggests
that non-oxidative glucose utilization may be important
during development to support synaptic remodelling
(Vaishnavi et al., 2010; Goyal et al., 2014). This may imply
that the nucleotide biosynthesis derived by PPP activity might
be crucial in neurons for synaptic plasticity (Magistretti,
2014). Indeed, the PPP/glycolysis ratio has been found to be
higher in neonatal brain compared to adult brain (Baquer
et al., 1977; Morken et al., 2014).
The current model of neuron/astrocyte bioenergetics has
been questioned by some groups (Dienel, 2012), as it has been
shown that during network activation neurons may be as
capable as astrocytes at employing glucose as an energy sub-
strate (Ivanov et al., 2014). Accordingly, glycolysis-generated
ATP appears of fundamental importance for vesicle motil-
ity (Zala et al., 2013). Therefore, as mitochondria may be
unevenly distributed in the neuronal cells, the glycolytic
machinery may provide the constant energy needed for fast
axonal transport (Zala et al., 2013).
Overall, our understanding of human brain energy
metabolism is still limited. Perhaps, recent advances in
stem cells and neuronal differentiation (Jakel, Schneider &
Svendsen, 2004; Sandoe & Eggan, 2013) might be helpful in
providing human CNS cells for the study of neuroenergetics
at the cellular and molecular level. This might potentially
clarify the role of the PPP in the CNS and the interplay
between different human brain cell types in the basal state
and under conditions stimulating remodelling of energy flux.
X. CONCLUSIONS
The PPP is a central component of metabolism in the
majority of single- and multicellular organisms. Despite the
pathway is central and evolutionary ancient, it possesses a
high level of flexibility, which renders it an attractive target
for biotechnology and medicine. In summary
(1) The main biochemical function of the PPP is the
biosynthesis of nucleic-acid and amino-acid sugar phosphate
precursors.
(2) This function of the PPP is bound to the provision of
biochemical reducing equivalents in form of NADPH, which
renders the PPP an important player in maintaining redox
homeostasis.
(3) The PPP is highly flexible, dynamic, and is adapting
to varying nutrient supply and stress conditions. This
coordinates these functions and is required meet cellular
metabolic demands in the constantly changing environment.
(4) The PPP is important for biotechnology, as its
flexibility can be exploited to tune NADPH production, and
for medical research, as the PPP activity is altered by bacterial
and eukaryotic parasites during the infection process, when
stem cells differentiate, when cancer cells maintain redox
homeostasis, and in neurons to sustain energy metabolism.
(5) Unveiling the complex regulation of the PPP, which
despite 80 years of detailed basic and medical research is still
not fully understood, appears hence essential for addressing
metabolic adaptation and its consequences on cellular and
organismic physiology.
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